Online citations, reference lists, and bibliographies.

2019 ESC Guidelines On Diabetes, Pre-diabetes, And Cardiovascular Diseases Developed In Collaboration With The EASD.

F. Cosentino, P. Grant, V. Aboyans, C. J. Bailey, A. Ceriello, V. Delgado, M. Federici, G. Filippatos, D. E. Grobbee, T. Hansen, H. Huikuri, I. Johansson, P. Jüni, M. Lettino, N. Marx, L. Mellbin, C. J. Östgren, B. Rocca, M. Roffi, N. Sattar, P. Seferovic, M. Sousa-Uva, P. Valensi, D. Wheeler
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Authors/Task Force Members: Francesco Cosentino* (ESC Chairperson) (Sweden), Peter J. Grant* (EASD Chairperson) (United Kingdom), Victor Aboyans (France), Clifford J. Bailey (United Kingdom), Antonio Ceriello (Italy), Victoria Delgado (Netherlands), Massimo Federici (Italy), Gerasimos Filippatos (Greece), Diederick E. Grobbee (Netherlands), Tina Birgitte Hansen (Denmark), Heikki V. Huikuri (Finland), Isabelle Johansson (Sweden), Peter Jüni (Canada), Maddalena Lettino (Italy), Nikolaus Marx (Germany), Linda G. Mellbin (Sweden), Carl J. € Ostgren (Sweden), Bianca Rocca (Italy), Marco Roffi (Switzerland), Naveed Sattar (United Kingdom), Petar M. Seferovi c (Serbia), Miguel Sousa-Uva (Portugal), Paul Valensi (France), David C. Wheeler (United Kingdom)
This paper references
10.1016/S0140-6736(09)60697-8
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
K. Ray (2009)
10.1007/s00125-011-2313-3
Do men develop type 2 diabetes at lower body mass indices than women?
J. Logue (2011)
Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K
MR MacDonald (2010)
Dabigatranversuswarfarin in patients with atrial fibrillation
SJ Connolly (2009)
Torp-Pedersen C, Pehrson S; DANISH Investigators. Defibrillator implantation in patients with nonischemic systolic heart failure
L Kober (2016)
food groups, and eating patterns in the management of diabetes: a systematic review of the literature
M L Wheeler (2010)
10.1093/eurheartj/ehr112
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
M. Chapman (2011)
Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year followup of the SYNTAX trial
S J Head (2014)
10.1093/eurheartj/ehw210
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
P. Kirchhof (2016)
10.1056/NEJMOA1610227
Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.
G. Stone (2016)
10.1056/NEJMoa1001282
Effects of combination lipid therapy in type 2 diabetes mellitus.
H. Ginsberg (2010)
10.1016/S0140-6736(05)67667-2
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
A. Keech (2005)
10.1161/01.RES.0000207406.94146.C2
Diabetic cardiomyopathy: the search for a unifying hypothesis.
I. Poornima (2006)
10.1093/EURHEARTJ/EHI376
Diabetes, glucose level, and risk of sudden cardiac death.
X. Jouven (2005)
10.2337/DIACARE.26.4.1313
Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia.
E. Cosson (2003)
10.1093/ejcts/ezx314
2017 EACTS Guidelines on perioperative medication in adult cardiac surgery.
M. Sousa-Uva (2018)
10.1016/S1062-1458(01)00477-9
Effect of carvedilol on survival in severe chronic heart failure.
M. Packer (2001)
10.1007/s00125-014-3259-z
Association of heart failure severity with risk of diabetes: a Danish nationwide cohort study
M. Demant (2014)
10.1093/oxfordjournals.aje.a116294
Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study.
F. G. Fowkes (1992)
10.1093/oxfordjournals.eurheartj.a060374
GUSTO (Global Utilization of Streptokinase and Tissue plasminogen activator in Occluded arteries): logic wins at last.
J. Bassand (1994)
10.1016/j.athoracsur.2012.03.082
Bilateral internal thoracic artery grafting is associated with significantly improved long-term survival, even among diabetic patients.
J. Puskas (2012)
10.1093/eurheartj/ehu213
Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial.
S. Head (2014)
10.1161/CIRCULATIONAHA.112.093245
The Assessment of Endothelial Function: From Research Into Clinical Practice
A. Flammer (2012)
10.1016/j.ejvs.2013.12.007
Diabetes and abdominal aortic aneurysms.
P. de Rango (2014)
10.1007/s001250051344
Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study
J. Gerritsen (2000)
10.1002/14651858.CD004017.PUB2
Home versus center based physical activity programs in older adults.
N. Ashworth (2005)
10.1016/J.JACC.2005.10.008
Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus.
R. Scognamiglio (2006)
10.1067/MHJ.2001.116072
Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators.
V. Dz̆avík (2001)
10.2337/dc09-2328
Cardiovascular Disease Mortality in Europeans in Relation to Fasting and 2-h Plasma Glucose Levels Within a Normoglycemic Range
F. Ning (2010)
10.1016/j.jvs.2010.01.075
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A description of the severity and extent of disease using the Bollinger angiogram scoring method and the TransAtlantic Inter-Society Consensus II classification.
A. Bradbury (2010)
10.2337/dc11-0330
Reflex and Tonic Autonomic Markers for Risk Stratification in Patients With Type 2 Diabetes Surviving Acute Myocardial Infarction
P. Barthel (2011)
10.1016/j.ahj.2017.12.006
ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes
L. Bowman (2018)
10.1097/JNR.0000000000000193
Empowerment Program for People With Prediabetes: A Randomized Controlled Trial
M. Chen (2017)
10.2337/dc13-0092
Intensive Structured Self-Monitoring of Blood Glucose and Glycemic Control in Noninsulin-Treated Type 2 Diabetes
E. Bosi (2013)
10.1016/j.jacc.2012.11.044
Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes.
M. Kamalesh (2013)
10.1056/nejm199702203360801
The effect of digoxin on mortality and morbidity in patients with heart failure.
G. Perry (1997)
10.1016/S0140-6736(94)92521-6
Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease
J. Tuomilehto (1994)
10.1177/1741826711430926
Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR (Part II)
L. Vanhees (2012)
Dowomen exhibit greater differences in established andnovel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women’s Heart Health Study
SG Wannamethee (2012)
FolsomAR, SiscovickDS,RosamondWD.Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study
AM Kucharska-Newton (2010)
Flash glucosesensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial
T Haak (2017)
10.1161/ATVBAHA.107.156059
Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein.
F. Cosentino (2008)
Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group.
L. Amato (1997)
10.1161/CIRCHEARTFAILURE.114.001104
Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist
O. Vardeny (2014)
10.1016/S1885-5857(09)60059-1
[ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012].
J. J. V. McMurray (2012)
10.1055/s-0028-1087203
Tools for predicting the risk of type 2 diabetes in daily practice.
P. Schwarz (2009)
10.2337/dc14-0199
Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial
Y. Hirakawa (2014)
10.1016/j.amjcard.2009.01.342
Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).
A. Dasgupta (2009)
CANVAS Program Collaborative Group. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program
K W Mahaffey (2018)
10.1056/NEJM200502243520818
Preventing microalbuminuria in type 2 diabetes.
M. Mauer (2005)
10.1093/ehjci/jes165
Abnormal glucose metabolism is associated with reduced left ventricular contractile reserve and exercise intolerance in patients with chronic heart failure.
M. Egstrup (2013)
10.1186/1475-2840-13-102
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
B. Zinman (2014)
10.1111/jocn.13487
An evaluation of the effectiveness of self‐management interventions for people with type 2 diabetes after an acute coronary syndrome: a systematic review
Mu'ath Tanash (2017)
10.1136/jnnp-2014-307856
Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial
H. Arima (2014)
10.5603/KP.2014.0225
[2014 ESC Guidelines on the diagnosis and treatment of aortic diseases].
R. Erbel (2014)
Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria
K. Borch-Johnsen (1999)
10.1161/CIRCULATIONAHA.113.006689
Five-Year Outcomes in Patients With Left Main Disease Treated With Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Trial
M. Morice (2014)
10.1007/s00125-004-1451-2
Simple non-invasive assessment of advanced glycation endproduct accumulation
R. Meerwaldt (2004)
10.1038/ajh.2011.8
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.
G. Tocci (2011)
10.1016/j.jcin.2009.04.007
A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study).
T. Takagi (2009)
10.1002/14651858.CD010523.pub2
Personalised care planning for adults with chronic or long-term health conditions.
A. Coulter (2015)
10.1016/S0140-6736(10)60576-4
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
F. Ismail-Beigi (2010)
10.1016/j.jacc.2010.09.073
The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals.
C. Kastorini (2011)
10.1016/j.amjcard.2009.08.672
Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.
Steven C. Halbert (2010)
10.1161/CIRCULATIONAHA.113.004420
Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial
L. Wallentin (2014)
10.1016/j.jcin.2014.08.006
Comparison of sirolimus-eluting stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 7-year follow-up of a randomized trial.
S. Blazek (2015)
10.1111/dme.13340
Effectiveness of group‐based self‐management education for individuals with Type 2 diabetes: a systematic review with meta‐analyses and meta‐regression
K. Odgers-Jewell (2017)
10.1016/j.ejheart.2007.09.009
Advanced glycation end‐products (AGEs) and heart failure: Pathophysiology and clinical implications
Jasper W.L. Hartog (2007)
10.1056/NEJMc1605904
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
M. Bursztyn (2016)
10.1007/s00125-017-4537-3
Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach
G. Mancia (2017)
10.1136/bmj.e4624
Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance
H. Chatterton (2012)
10.1007/s00125-006-0483-1
QTc interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up
C. Stettler (2006)
10.1056/NEJM199811123392002
Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators.
H. Barnett (1998)
10.1016/j.amjcard.2011.06.037
Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy).
M. Maeng (2011)
10.1001/jama.2013.1954
Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
M. Gheorghiade (2013)
10.1056/NEJMoa1415447
Trial of everolimus-eluting stents or bypass surgery for coronary disease.
S. Park (2015)
GenderSpecific short and long-term mortality in diabetic versus nondiabetic patients with incident acute myocardial infarction in the reperfusion era (the MONICA/KORA Myocardial Infarction Registry)
C Meisinger (2010)
CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes
B Neal (2017)
10.1136/hrt.2010.194563
Comparison of glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial infarction: a contemporary meta-analysis of randomised controlled trials
Y. Zhao (2010)
10.1056/NEJMoa1203858
Basal insulin and cardiovascular and other outcomes in dysglycemia.
H. Gerstein (2012)
10.2337/dc18-0548
Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial
J. Zhou (2018)
10.1161/CIRCULATIONAHA.109.913376
Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome
J. Ferreiro (2011)
10.1016/S0140-6736(09)61913-9
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial
M. Konstam (2009)
10.1016/j.jacc.2013.02.011
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
Mikhail Kosiborod (2013)
10.1056/NEJMoa1409312
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
L. Mauri (2014)
10.1177/1358863X14538330
Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty
S. Singh (2014)
10.1007/s00125-009-1308-9
Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus
H. Lutgers (2009)
10.1007/s00125-018-4642-y
Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study
Jens Oellgaard (2018)
10.1371/journal.pmed.1002091
Correction: The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
D. V. Rados (2016)
10.1136/bmj.321.7258.412
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
A. Adler (2000)
10.1136/bmj.324.7329.71
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
C. Baigent (2002)
10.1016/J.AMJMED.2006.08.033
Fixed-dose combinations improve medication compliance: a meta-analysis.
S. Bangalore (2007)
10.1161/CIRCULATIONAHA.109.933796
Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function: Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
S. James (2010)
10.1016/j.jacc.2009.11.026
5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome.
P. Damman (2010)
10.1161/CIRCULATIONAHA.105.563213
Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms
J. Kim (2006)
10.1093/eurheartj/ehn567
Development of life-expectancy tables for people with type 2 diabetes.
J. Leal (2009)
10.1016/j.jacc.2014.09.074
Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending disease.
E. Hannan (2014)
10.1056/NEJMoa0901316
Early versus delayed, provisional eptifibatide in acute coronary syndromes.
R. Giugliano (2009)
10.1186/1745-6215-12-23
Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening
M. Lièvre (2011)
Managing hypoglycaemia.
B. Frier (2005)
10.1136/hrt.2008.152835
Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial
L. Mellbin (2008)
10.1016/j.jacc.2014.06.1182
Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial.
G. Dangas (2014)
10.1016/j.ajem.2017.05.024
The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI
Runjun Li (2017)
10.1016/j.jacc.2009.10.014
Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial.
A. Kapur (2010)
10.1161/JAHA.113.000759
Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials
G. Thanassoulis (2014)
10.1161/JAHA.116.004007
Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
M. Mazidi (2017)
10.1161/CIRCULATIONAHA.117.028136
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
M. Nauck (2017)
10.1016/J.IJCARD.2005.09.024
Prognosis of patients with atherothrombotic disease: a prospective survey in a non-hospital setting.
J. Ferrières (2006)
10.1089/DIA.2004.6.874
Prevention of type 2 diabetes: issues and strategies for identifying persons for interventions.
M. Engelgau (2004)
10.1161/HC0302.102575
Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study
G. Assmann (2002)
Spironolactone in patients with heart failure.
G. Glick (2000)
10.1016/j.jcjd.2017.11.004
Chronic Kidney Disease in Diabetes.
P. McFarlane (2018)
10.1002/14651858.cd004097
Dietary advice for treatment of type 2 diabetes mellitus in adults.
H. Moore (2004)
10.1016/j.ijcard.2008.11.211
Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials.
S. Saha (2010)
10.1016/j.diabres.2016.04.055
Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality.
J. Eriksson (2016)
10.1007/BF00418273
Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients
D. Ewing (2004)
10.2337/DIACARE.25.10.1737
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
G. Viberti (2002)
10.1001/JAMA.285.18.2370
Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.
A. Go (2001)
10.1016/S0002-9149(02)02567-5
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.
Deepak L. Bhatt (2002)
10.5603/KP.2015.0190
[2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death].
S. Priori (2015)
10.1016/j.amjcard.2018.01.017
Smoking Cessation in Patients With Acute Coronary Syndrome.
C. Franck (2018)
10.1161/CIRCINTERVENTIONS.115.003255
Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients
K. Koskinas (2016)
10.1093/eurheartj/ehn153
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
M. R. Macdonald (2008)
10.1016/S0140-6736(08)61412-9
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials
N. Chaturvedi (2008)
10.1001/archinte.151.9.1769
Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials.
K. Radack (1991)
Effect of beta blockers on incidence of newcoronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease
WS Aronow (2001)
2.3 Management of lower extremity artery disease in diabetes
. . . . . . . . . . . . . . . . . . . . . Aortic
10.1016/j.athoracsur.2011.09.037
What predicts long-term survival after heart transplantation? An analysis of 9,400 ten-year survivors.
A. Kilic (2012)
10.1007/s11897-009-0019-3
Pharmacologic management of patients with both heart failure and diabetes
Michael R. Macdonald (2009)
Stroke Council. Health literacy and cardiovascular disease: fundamental relevance to primary and secondary prevention: a scientific statement from the
(2018)
Management of hyperglycaemia in type 54 ESC
S E Inzucchi
Doron Aronson; Italy: Italian Federation of Cardiology
Israel
[Glucagon-like peptide-1 receptor agonists].
Yamato Mashimo (2015)
10.1016/j.atherosclerosis.2013.08.015
The utility of ultrasonic tissue characterization of carotid plaque in the prediction of cardiovascular events in diabetic patients.
Y. Irie (2013)
Ranibizumab: in diabetic macular oedema. Drugs 2012;72:509–523
JE Frampton (2012)
10.2337/dc10-2415
Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
R. Wing (2011)
10.1093/eurheartj/ehu051
Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial.
C. Jennings (2014)
[Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study].
M. Ai (2010)
10.1016/S0140-6736(11)60739-3
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
C. Baigent (2011)
10.1056/NEJM199006213222503
Thromboxane biosynthesis and platelet function in type II diabetes mellitus.
G. Daví (1990)
10.7326/0003-4819-158-7-201304020-00004
Discontinuation of Statins in Routine Care Settings
Huabing Zhang (2013)
10.1161/CIR.0000000000000330
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.
B. Scirica (2015)
10.2337/dc14-S120
Nutrition Therapy Recommendations for the Management of Adults With Diabetes
A. Evert (2013)
10.1001/jama.2014.18574
Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis.
C. Emdin (2015)
10.1016/S0140-6736(11)60698-3
Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial
S. Griffin (2011)
10.2337/db13-1093
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions
D. Nathan (2013)
10.2337/DIACARE.29.04.06.DC05-1894
The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction.
N. Cheung (2006)
10.1111/j.1464-5491.2010.03222.x
Influence of blood glucose on heart rate and cardiac autonomic function. The DESIR study
P. Valensi (2011)
10.2337/dc16-1728
Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association
S. Colberg (2016)
10.1055/s-0029-1240975
Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe.
J. Lindström (2010)
10.1016/J.EHJ.2004.07.027
The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart.
M. Bartnik (2004)
10.1161/01.STR.23.12.1752
Distribution and Correlates of Sonographically Detected Carotid Artery Disease in the Cardiovascular Health Study
D. O'leary (1992)
10.1007/s00125-004-1607-0
Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria
P. Gæde (2004)
10.1016/S0140-6736(09)61965-6
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
N. Sattar (2010)
10.1056/NEJMoa0804626
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.
P. Serruys (2009)
10.1172/JCI118871
Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells.
G. Zeng (1996)
No excess12-yearmortality inmen with impairedglucose tolerance who participated in the Malmo Preventive Trial with diet and exercise
KF Eriksson (1998)
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
S Yusuf (2000)
Vilsboll T; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
S P Marso (2016)
Prevalence of and risk factors associated with carotid artery stenosis: the Tromso Study
EB Mathiesen (2001)
20 6.3.2.1 Effects of lifestyle intervention and weight loss
. . . . . . . . . . . . Management
RM; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes
C P Cannon (2015)
10.1056/NEJMoa1107039
Apixaban versus warfarin in patients with atrial fibrillation.
C. Granger (2011)
10.1016/S0084-3741(09)79281-9
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
S. Schinner (2009)
10.1016/S0140-6736(12)60324-9
Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis
T. Palmerini (2012)
10.2165/11587580-000000000-00000
Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus
A. Hernández (2011)
10.1136/jnnp.2004.039339
Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study
G. Suarez (2005)
10.1056/NEJMoa1800256
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Aidin Rawshani (2018)
10.1016/j.ejcnurse.2011.06.008
Person-Centered Care — Ready for Prime Time
I. Ekman (2011)
10.1161/CIRCULATIONAHA.118.038868
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Thomas A. Zelniker (2019)
10.1016/J.ACCREVIEW.2005.06.015
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.
K. Malmberg (2005)
10.1016/j.jacc.2017.12.024
Coronary Artery Bypass Surgery Improves Outcomes in Patients With Diabetes and Left Ventricular Dysfunction.
J. Nagendran (2018)
10.1007/s00125-010-1960-0
External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes
S. van Dieren (2010)
10.2337/dc09-1410
Performance of an A1C and Fasting Capillary Blood Glucose Test for Screening Newly Diagnosed Diabetes and Pre-Diabetes Defined by an Oral Glucose Tolerance Test in Qingdao, China
X. Zhou (2009)
10.1111/j.1365-2125.1994.tb04276.x
Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group.
J. Detry (1994)
10.2337/dc15-0327
Carotid Plaque Calcification Predicts Future Cardiovascular Events in Type 2 Diabetes
Saula Vigili de Kreutzenberg (2015)
10.1016/S1078-5884(03)00356-3
Smoking cessation strategies in patients with peripheral arterial disease: an evidence-based approach.
S. Hobbs (2003)
10.1093/eurheartj/ehy596
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology
C. Maack (2018)
10.7326/0003-4819-132-10-200005160-00017
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation
R. Hart (2000)
10.1016/j.amjcard.2008.02.097
Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects.
F. Abbasi (2008)
10.1007/s11739-011-0527-5
Screening for asymptomatic coronary artery disease can reduce cardiovascular mortality and morbidity in type 2 diabetic patients
C. Gazzaruso (2011)
10.1016/j.jtcvs.2010.10.005
Superiority of moderate control of hyperglycemia to tight control in patients undergoing coronary artery bypass grafting.
C. Bhamidipati (2011)
10.1007/s11892-017-0898-8
Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions
Rebecca Herbst (2017)
10.1177/1479164114551746
Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: Long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort
V. Ritsinger (2015)
10.1093/eurheartj/ehq368
Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the euro heart survey on diabetes and the heart.
M. Anselmino (2010)
10.1056/NEJMoa1006524
Long-term effects of intensive glucose lowering on cardiovascular outcomes.
H. Gerstein (2011)
10.1136/heartjnl-2011-300163
Comparison of diagnostic criteria to detect undiagnosed diabetes in hyperglycaemic patients with acute coronary syndrome
M. de Mulder (2011)
10.1136/bmj.d6898
Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials
B. Hemmingsen (2011)
10.1016/j.pcad.2010.02.010
The Framingham Study, diabetes mellitus and cardiovascular disease: turning back the clock.
A. Kengne (2010)
Cardiac arrhythmias in hypoglycaemia.
S. Heller (2002)
10.1111/j.1538-7836.2010.03742.x
Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus
F. Santilli (2010)
10.1016/j.jacc.2008.07.062
Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus.
L. Rijzewijk (2008)
10.1161/CIRCULATIONAHA.117.029652
Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions
William M. Schultz (2018)
10.1001/jama.2018.18269
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
J. Rosenstock (2019)
10.2337/dc09-1278
Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial
M. Riddle (2010)
10.1056/NEJMoa1612917
Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
R. Holman (2017)
Sudden cardiac death in diabetes
DEVOTE Study Group. Efficacy and safety of degludec versus glargine in type 2 diabetes
S P Marso (2017)
10.1016/S2213-8587(19)30093-2
Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study.
Q. Gong (2019)
10.1056/NEJMoa0802987
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
A. Patel (2008)
10.1016/j.jacc.2010.10.006
Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
Dean J. Kereiakes (2010)
10.1714/2464.25804
[2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)].
M. Roffi (2016)
10.1371/journal.pmed.0050207
The Relationship between Proteinuria and Coronary Risk: A Systematic Review and Meta-Analysis
V. Perkovic (2008)
Antiplatelet and antithrombotic drugs (see section 6.5)
10.1016/S0140-6736(07)60716-8
The safety of statins in clinical practice
J. Armitage (2007)
10.1136/bmj.39063.689375.55
Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis
C. Gillies (2007)
10.1056/NEJMOA011303
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Edmund J. Lewis (2001)
10.1161/CIRCINTERVENTIONS.115.002626
Everolimus Eluting Stents Versus Coronary Artery Bypass Graft Surgery for Patients With Diabetes Mellitus and Multivessel Disease
S. Bangalore (2015)
10.1016/J.JACC.2005.03.052
U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction.
D. Pinto (2005)
10.1056/NEJMoa0806470
10-year follow-up of intensive glucose control in type 2 diabetes.
R. Holman (2008)
10.1186/1741-7015-11-207
Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial
E. Toledo (2013)
10.1016/j.jacc.2017.10.029
Surgical Versus Percutaneous Coronary Revascularization in Patients With Diabetes and Acute Coronary Syndromes.
K. Ramanathan (2017)
10.2337/db09-1904
Are Individuals With Diabetes Seeing Better?
R. Klein (2010)
10.1111/j.1464-5491.2011.03304.x
Shifting from glucose diagnostic criteria to the new HbA1c criteria would have a profound impact on prevalence of diabetes among a high‐risk Spanish population
B. Costa (2011)
10.1016/S0140-6736(05)66702-5
A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack
P. Rothwell (2005)
ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
J. Nielsen (2014)
New treatment guidelines for a patient with diabetes and hypertension.
C. Mogensen (2003)
10.1001/jama.2012.426
Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial.
H. Selker (2012)
10.1016/j.jcin.2012.09.008
Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial.
S. Blazek (2013)
10.1161/CIRCULATIONAHA.116.025760
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial
Y. Saito (2017)
10.1155/2015/743503
Evidence for a Specific Diabetic Cardiomyopathy: An Observational Retrospective Echocardiographic Study in 656 Asymptomatic Type 2 Diabetic Patients
I. Pham (2015)
10.1016/S0140-6736(00)02212-1
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients
M. Flather (2000)
10.1161/01.CIR.0000051367.92927.07
High Glucose Causes Upregulation of Cyclooxygenase-2 and Alters Prostanoid Profile in Human Endothelial Cells: Role of Protein Kinase C and Reactive Oxygen Species
F. Cosentino (2003)
10.1001/jama.300.2.197
Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis.
F. G. Fowkes (2008)
10.2337/dc17-0245
The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA1c in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV
Bahira Shahim (2017)
10.1056/NEJMoa1112277
Rivaroxaban in patients with a recent acute coronary syndrome.
J. Mega (2012)
10.1111/j.1538-7836.2007.02728.x
Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin
V. Evangelista (2007)
10.2337/db13-0468
Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk
Elaine Chow (2014)
10.1016/S0140-6736(09)60953-3
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
P. Home (2009)
10.1093/oxfordjournals.qjmed.a068570
The influence of autonomic neuropathy on mortality in insulin-dependent diabetes.
I. O'brien (1991)
10.1016/S0140-6736(10)60656-3
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Min Jun (2010)
10.1056/NEJMoa1007432
Apixaban in patients with atrial fibrillation.
S. Connolly (2011)
10.1093/ejcts/ezx334
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.
M. Valgimigli (2018)
10.2337/DIACARE.26.11.3160
Follow-up report on the diagnosis of diabetes mellitus.
S. Genuth (2003)
10.1001/archinternmed.2011.16
Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort.
I. D. de Boer (2011)
10.1016/J.JACC.2004.05.055
Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials.
F. McAlister (2004)
10.1016/S0140-6736(03)14285-7
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
S. Yusuf (2003)
10.1016/j.jacc.2009.06.036
Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.
J. M. Lee (2009)
10.2337/DIACARE.28.3.612
The association between glucose abnormalities and heart failure in the population-based Reykjavik study.
I. Thrainsdottir (2005)
Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial
RJ Sigal (2007)
Czech Republic: Czech Society of Cardiology, Ale s Linhart
10.2337/dci17-0057
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum
W. Cefalu (2017)
10.1016/S0140-6736(96)09457-3
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
Caprie Steering Committee (1996)
Sabatine MS; DECLAREÀTIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes
S D Wiviott (2019)
Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes
W Duckworth (2009)
10.1016/S0140-6736(14)61368-4
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
J. Fulcher (2015)
10.1016/j.ahj.2011.07.030
Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis.
D. Castagno (2011)
10.1378/CHEST.119.5.1576
Clinical utility of the exercise ECG in patients with diabetes and chest pain.
D. Lee (2001)
10.1016/S0735-1097(02)02304-5
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
A. Maggioni (2002)
10.1016/S0140-6736(03)14283-3
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
J. McMurray (2003)
10.2337/db07-0707
The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients
Joseph Dichiara (2007)
10.1016/j.numecd.2008.01.012
Guideline for management of postmeal glucose.
A. Ceriello (2008)
10.2337/dc11-s220
Hypoglycemia and Cardiovascular Risks
B. Frier (2011)
10.1016/j.ahj.2013.06.004
Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience.
W. Mampuya (2013)
10.1177/1358863X17751259
Diagnostic accuracy of the postexercise ankle–brachial index for detecting peripheral artery disease in suspected claudicants with and without diabetes
P. Tehan (2018)
10.2337/dc12-0178
Associations Between the Ankle-Brachial Index and Cardiovascular and All-Cause Mortality Are Similar in Individuals Without and With Type 2 Diabetes
N. M. Hanssen (2012)
10.1046/j.1440-1681.2002.03618.x
A Metabolic Mechanism For Cardiac K+ Channel Remodelling
G. Rozanski (2002)
10.1093/europace/euu194
EHRA/HRS/APHRS expert consensus on ventricular arrhythmias.
Christian Torp Pedersen (2014)
10.1016/j.jacc.2016.03.529
Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.
Deepak L. Bhatt (2016)
10.1161/01.cir.97.22.2202
Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group.
MariaGrazia Franzosi (1998)
10.1001/jama.2016.3608
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
S. Nissen (2016)
10.1097/HJH.0000000000000379
Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels – overview and meta-analyses of randomized trials
C. Thomopoulos (2014)
10.1093/eurheartj/ehv728
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
D. Fitchett (2016)
10.1001/ARCHINTE.167.13.1353
Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial.
J. Timmer (2007)
10.1007/s00125-005-0026-1
Contraindications can damage your health—is metformin a case in point?
A. Holstein (2005)
10.1016/J.ACCREVIEW.2005.10.023
The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
C. Daly (2005)
10.1016/S0140-6736(98)07368-1
Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study
P. Gæde (1999)
10.1002/ejhf.657
Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial
A. Jorsal (2017)
10.1097/JCN.0b013e3181ec1337
Does Nurse Case Management Improve Implementation of Guidelines for Cardiovascular Disease Risk Reduction?
K. Berra (2011)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
R. Turner (1998)
10.1016/j.kint.2016.11.023
Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.
Jens Oellgaard (2017)
10.1016/j.jand.2017.03.023
Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: Nutrition Intervention Evidence Reviews and Recommendations.
Janice MacLeod (2017)
10.1016/s1062-1458(03)00293-9
Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).
E. Vermes (2003)
10.1056/NEJMRA071014
Platelet activation and atherothrombosis.
G. Daví (2007)
10.1136/bmj.314.7093.1512
Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus
K. Malmberg (1997)
10.1016/S2468-1253(18)30037-2
Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials
B. Scally (2018)
10.1016/S0140-6736(08)61411-7
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial
A. K. Sjølie (2008)
Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399–2405
P Massin (2010)
Brott TG; CREST Investigators. Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial
B K Lal (2012)
Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes
S P Marso (2016)
Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group
O Vaccaro (2017)
10.1016/j.jacc.2015.03.033
Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease: 5-Year Outcomes of the PRECOMBAT Study.
Jung Min Ahn (2015)
10.1161/CIRCULATIONAHA.113.004255
Effect of Bilateral Internal Mammary Artery Grafts on Long-Term Survival: A Meta-Analysis Approach
G. Yi (2014)
10.1056/NEJMoa1615692
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
S. Marso (2017)
10.1007/s12529-016-9583-6
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo F. Piepoli (2017)
10.1093/eurheartj/ehx095
2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b
V. Aboyans (2018)
Putting evidence into practice: Smoking Cessation. Summer 2007,
K. Brunnhuber (2007)
10.1001/archinternmed.2012.3147
Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis.
K. McBrien (2012)
10.1161/01.HYP.0000215363.69793.bb
Long-Term Risk of Mortality Associated With Selective and Combined Elevation in Office, Home, and Ambulatory Blood Pressure
G. Mancia (2006)
10.1093/AJE/153.4.353
Coffee consumption and serum lipids: a meta-analysis of randomized controlled clinical trials.
S. Jee (2001)
10.1161/01.HYP.0000057420.27692.AD
Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)
G. Mancia (2003)
10.1001/ARCHINTE.165.12.1410
Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.
F. Turnbull (2005)
10.1042/CS1010671
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).
R. Stevens (2001)
10.1001/jamacardio.2017.1891
The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure.
S. Verma (2017)
10.1001/JAMA.286.4.421
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.
H. Gerstein (2001)
10.1056/NEJM200101043440101
Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet
F. Sacks (2001)
10.1111/j.1464-5491.2005.01494.x
Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study
R. Guzder (2005)
10.1002/dmrr.2705
Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review
R. Hinchliffe (2016)
10.1056/NEJMoa1608029
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.
L. Køber (2016)
10.2337/diacare.21.4.597
Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM
P. Tatti (1998)
10.1371/journal.pone.0005656
Ten-Year Mortality and Cardiovascular Morbidity in the Finnish Diabetes Prevention Study—Secondary Analysis of the Randomized Trial
M. Uusitupa (2009)
10.1161/CIRCULATIONAHA.117.030950
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes Vytorin Efficacy International Trial)
R. Giugliano (2018)
10.1016/S2213-8587(17)30309-1
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
R. Holman (2017)
10.1056/NEJMoa1307684
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
B. Scirica (2013)
10.1161/ATVBAHA.111.224808
Dual Metabolic Defects Are Required to Produce Hypertriglyceridemia in Obese Subjects
M. Taskinen (2011)
10.1016/j.jchf.2017.08.004
Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial.
J. McMurray (2018)
10.1093/eurheartj/ehp355
Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry
M. Alberts (2009)
10.1056/NEJMoa1615664
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
M. Sabatine (2017)
10.1111/j.1365-2796.2006.01763.x
Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double‐blind trial
M. Catalano (2007)
Patient-Centered Medicine: Transforming the Clinical Method
C. A. Johnson (1995)
10.1016/j.jacc.2017.08.037
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.
C. Patrono (2017)
10.2337/dc07-2452
Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes
P. Gæde (2008)
10.1093/eurheartj/ehr479
Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
G. Sarno (2012)
10.2337/DIACARE.26.12.3230
The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity.
J. Lindström (2003)
10.1001/JAMA.286.2.180
Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.
R. D'Agostino (2001)
10.1001/JAMA.290.4.486
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
J. Chiasson (2003)
10.1093/humrep/det255
Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method.
E. Lerchbaum (2013)
10.1161/CIRCULATIONAHA.109.913111
The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease: Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction
B. Chaitman (2009)
10.1056/NEJMoa1610021
Randomized Trial of Bilateral versus Single Internal-Thoracic-Artery Grafts.
D. Taggart (2016)
10.1056/NEJMoa1211585
Strategies for multivessel revascularization in patients with diabetes.
M. Farkouh (2012)
10.1001/JAMA.295.13.JOC60034
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
A. Kastrati (2006)
10.1111/dme.12828
Randomized controlled trial comparing impact on platelet reactivity of twice‐daily with once‐daily aspirin in people with Type 2 diabetes
M. Bethel (2016)
Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress.
G. Camici (2007)
10.1161/CIRCULATIONAHA.105.548099
Exertional Leg Pain in Patients With and Without Peripheral Arterial Disease
J. Wang (2005)
A Study on Efficacy of Empowerment Training among Diabetes Patients
Hsiangchi Wu (2011)
10.1007/s00125-009-1647-6
Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance
A. Mari (2009)
10.1016/S0140-6736(00)02526-5
Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study
L. Hansson (2000)
10.1001/ARCHINTE.164.13.1457
Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events.
Kristen M Franklin (2004)
10.2337/dc17-2222
Global Diabetes Prevention Interventions: A Systematic Review and Network Meta-analysis of the Real-World Impact on Incidence, Weight, and Glucose
K. Galaviz (2018)
Hypoglycaemia and cognitive function. Diabetes Obes Metab 2005;7:493–503
RE Warren (2005)
1.2.1 Established oral glucose-lowering drugs
Reduction in ischemic 62 ESC
D L Bhatt
10.1093/ehjci/jey014
Non-invasive screening for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials
O. F. Clerc (2018)
10.1002/14651858.CD000535.pub2
Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery.
J. Brown (2003)
Standards of medical care in diabetes.
Aesha Drozdowski (2004)
10.1136/bmj.i6538
Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions
Eleanor Barry (2017)
Krum H; VIVIDD Trial Committees and Investigators. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial
Jjv Mcmurray (2018)
Schaper NC; International Working Group on the Diabetic Foot. Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review
R J Hinchliffe (2016)
10.1056/NEJMoa1603827
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
S. Marso (2016)
10.1056/NEJMoa1409077
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
J. McMurray (2014)
10.1056/NEJMoa071804
Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease.
E. Hannan (2008)
10.1161/01.CIR.91.10.2591
Sudden death, impaired glucose tolerance, and diabetes in Japanese American men.
J. Curb (1995)
10.1016/S1078-5884(11)60012-9
Chapter V: Diabetic foot.
M. Lepäntalo (2011)
10.1056/NEJMoa1709118
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
J. Eikelboom (2017)
10.1111/j.1365-2796.2012.02513.x
Current controversies in the use of haemoglobin A1c
M. Hare (2012)
10.1161/CIRCIMAGING.115.003528
Absence of Coronary Artery Calcium Identifies Asymptomatic Diabetic Individuals at Low Near-Term But Not Long-Term Risk of Mortality: A 15-Year Follow-Up Study of 9715 Patients
Valentina Valenti (2016)
10.1007/s00125-012-2579-0
High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes
L. B. Boonman-de Winter (2012)
10.1016/j.jcmg.2014.07.010
Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudy.
M. Zellweger (2014)
10.1111/dme.12410
Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomized trial
J. A. Black (2014)
10.1016/S0939-4753(04)80028-0
Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus.
J. I. Mann (2004)
10.1111/j.1747-4949.2009.00259.x
European Guidelines on Cardiovascular Disease Prevention
G. Boysen (2009)
10.1056/NEJMoa0808431
Glucose control and vascular complications in veterans with type 2 diabetes.
W. Duckworth (2009)
10.1093/oxfordjournals.eurheartj.a059505
Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies.
K. Malmberg (1989)
10.1007/s00125-009-1505-6
Intensive glucose control and macrovascular outcomes in type 2 diabetes
The Control Group (2009)
Armenia: Armenian Cardiologists Association, Parounak H. Zelveian; Austria: Austrian Society of Cardiology
37 8.2 Mechanisms of left ventricular dysfunction in diabetes mellitus
Ulf Landmesser (Germany), Christophe Leclercq (France), Maddalena Lettino (Italy)
Esc Committee For Practice
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution)
Agency European Medicines
10.1056/NEJMoa1808783
Bilateral versus Single Internal‐Thoracic‐Artery Grafts at 10 Years
D. Taggart (2019)
10.1136/bmj.308.6921.81
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
R. Altman (1994)
10.1056/NEJMsa1213829
Achievement of goals in U.S. diabetes care, 1999-2010.
M. Ali (2013)
10.1056/NEJMoa1407963
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
S. Zoungas (2014)
10.1056/NEJMoa1616011
Liraglutide and Renal Outcomes in Type 2 Diabetes
J. Mann (2017)
Preventionof type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health 2009;9:342
PennL (2009)
Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
J Tuomilehto (2001)
10.1007/978-1-60327-357-2_7
Diabetes and cardiovascular disease.
J. Sowers (1999)
10.1161/01.STR.0000257974.06317.49
Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)
R. Wilcox (2007)
10.2337/DIACARE.27.7.1844
Comparative study of prognostic value for coronary disease risk between the U.K. prospective diabetes study and Framingham models.
I. Protopsaltis (2004)
10.1161/01.CIR.99.23.3028
Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists.
S. Levy (1999)
10.1016/j.diabet.2010.12.006
Transthoracic echocardiographic abnormalities in asymptomatic diabetic patients: association with microalbuminuria and silent coronary artery disease.
M. T. Nguyễn (2011)
10.1136/BMJ.320.7236.676
Using the Framingham model to predict heart disease in the United Kingdom: retrospective study
S. Ramachandran (2000)
10.1111/j.1464-5491.2008.02417.x
Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study
C. Roumen (2008)
10.5603/KP.2016.0141
[2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure].
P. Ponikowski (2016)
10.2337/diacare.8.2.114
Age of Onset and Type of Diabetes
M. Laakso (1985)
10.1016/S0140-6736(09)60731-5
Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis
L. Bellamy (2009)
10.1056/NEJMoa1504720
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
B. Zinman (2015)
10.1161/CIRCRESAHA.116.303849
Epidemiology of peripheral artery disease.
M. Criqui (2015)
10.1161/CIRCULATIONAHA.109.865600
Mortality and Vascular Morbidity in Older Adults With Asymptomatic Versus Symptomatic Peripheral Artery Disease
C. Diehm (2009)
10.2196/jmir.4112
Overcoming Clinical Inertia: A Randomized Clinical Trial of a Telehealth Remote Monitoring Intervention Using Paired Glucose Testing in Adults With Type 2 Diabetes
D. Greenwood (2015)
10.1093/ije/dyr029
Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis.
E. Agardh (2011)
10.1056/NEJMoa1800389
Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra‐Virgin Olive Oil or Nuts
R. Estruch (2018)
10.2337/DIACARE.27.8.1954
Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study.
F. Wackers (2004)
10.1016/J.AMJCARD.2003.12.026
Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus.
J. Boyer (2004)
10.1093/eurheartj/ehw132
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
G. Filippatos (2016)
10.1161/CIRCULATIONAHA.106.628347
Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial
A. Ahmed (2006)
10.1186/s12933-017-0515-9
Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk
Katherine J. Kearney (2017)
10.2337/DIACARE.28.5.1151
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
P. Sever (2005)
10.1001/JAMA.1997.03550010054039
Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas.
R. Shorr (1997)
10.1056/NEJMOA011161
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
B. Brenner (2001)
10.1001/jama.2011.576
Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis.
D. Umpierre (2011)
10.1093/EJCTS/EZW313
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
P. Kirchhof (2016)
10.1016/j.ejheart.2007.07.017
Increasing glucose levels and BMI predict future heart failure Experience from the Reykjavík Study
I. Thrainsdottir (2007)
10.1093/eurjhf/hfs136
Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?
Anselm K. Gitt (2012)
Bhatt DL; REACH Registry Investigators. Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease
S Bangalore (2012)
10.1056/NEJMoa0706245
Effect of a multifactorial intervention on mortality in type 2 diabetes.
P. Gaede (2008)
Inzucchi SE; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial
L H Young (2009)
EACTS Guidelines on perioperative medication in adult cardiac surgery
M Sousa-Uva (2017)
Yusuf S; COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind
S J Connolly (2018)
10.1161/CIRCULATIONAHA.110.955542
Myocardial Steatosis and Biventricular Strain and Strain Rate Imaging in Patients With Type 2 Diabetes Mellitus
A. Ng (2010)
10.5551/jat.43141
Clinical Utility of Carotid Ultrasonography in the Prediction of Cardiovascular Events in Patients with Diabetes: A Combined Analysis of Data Obtained in Five Longitudinal Studies
N. Katakami (2018)
10.2337/db15-0936
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes
F. Zaccardi (2015)
10.1161/CIRCIMAGING.111.965608
Association Between Diffuse Myocardial Fibrosis by Cardiac Magnetic Resonance Contrast-Enhanced T1 Mapping and Subclinical Myocardial Dysfunction in Diabetic Patients: A Pilot Study
A. Ng (2012)
10.1093/eurheartj/ehy339
2018 ESC/ESH Guidelines for the management of arterial hypertension.
B. Williams (2018)
10.1016/j.pcd.2017.10.004
Effectiveness of individual strategies for the empowerment of patients with diabetes mellitus: A systematic review with meta-analysis.
Jéssica Azevedo Aquino (2018)
Impact of Subclinical Atherosclerosis on Cardiovascular Disease Events in IndividualsWithMetabolic Syndrome and Diabetes The Multi-Ethnic Study of Atherosclerosis
S. Malik (2011)
10.1016/S2213-8587(17)30327-3
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
K. Ueki (2017)
10.1016/j.diabres.2015.10.021
Glycemic load, exercise, and monitoring blood glucose (GEM): A paradigm shift in the treatment of type 2 diabetes mellitus.
D. Cox (2016)
10.1016/j.ejim.2015.05.006
Does coronary Atherosclerosis Deserve to be Diagnosed earlY in Diabetic patients? The DADDY-D trial. Screening diabetic patients for unknown coronary disease.
F. Turrini (2015)
10.1161/JAHA.117.008010
Unmeasured Confounders in Observational Studies Comparing Bilateral Versus Single Internal Thoracic Artery for Coronary Artery Bypass Grafting: A Meta‐Analysis
M. Gaudino (2018)
10.1016/S0140-6736(17)31490-3
Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials
A. Jobs (2017)
10.1016/j.numecd.2017.06.016
Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: A case-control study.
F. Zaccardi (2017)
10.1161/CIRCIMAGING.111.963587
Association of Imaging Markers of Myocardial Fibrosis With Metabolic and Functional Disturbances in Early Diabetic Cardiomyopathy
C. Jellis (2011)
10.1161/CIRCULATIONAHA.109.192521
Exercise Training for Type 2 Diabetes Mellitus: Impact on Cardiovascular Risk A Scientific Statement From the American Heart Association
T. Marwick (2009)
10.1007/s001250050924
The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT)
V. Kadirkamanathan (1998)
10.1016/S0002-9343(99)80348-9
The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study.
A. Krahn (1995)
10.1016/J.IJCARD.2004.10.024
Prevalence and characteristics of diabetic patients in a chronic heart failure population.
C. Kistorp (2005)
10.1056/NEJMOA030207
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
B. Pitt (2003)
10.2337/DIACARE.27.8.1879
The incidence of congestive heart failure in type 2 diabetes: an update.
G. Nichols (2004)
10.1093/eurheartj/ehr035
Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients.
E. Mills (2011)
10.1056/NEJMoa1107579
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
W. Boden (2011)
10.1001/jama.1994.03510350050036
Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.
E. Benjamin (1994)
10.1001/jama.2016.10260
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
K. Margulies (2016)
10.1056/NEJMoa1515920
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
C. Wanner (2016)
10.1016/S0140-6736(15)00805-3
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
X. Xie (2016)
10.1258/acb.2007.006212
Measurement of blood glucose: comparison between different types of specimens
B. Carstensen (2008)
10.1161/01.HYP.19.6.717
Cardiovascular Determinants of Carotid Artery Disease: The Rotterdam Elderly Study
M. Bots (1992)
A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
D. Clément (1996)
10.1161/01.CIR.103.21.2566
Prediction of Mortality by Exercise Echocardiography: A Strategy for Combination With the Duke Treadmill Score
T. Marwick (2001)
10.1001/jama.2012.12559
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.
S. Bangalore (2012)
10.1161/CIRCULATIONAHA.110.014506
Altered Mitochondrial Dynamics Contributes to Endothelial Dysfunction in Diabetes Mellitus
S. Shenouda (2011)
10.1016/S0140-6736(18)32261-X
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
A. Hernandez (2018)
10.1161/CIR.0b013e3182160726
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.
M. Miller (2011)
10.1093/EUROPACE/EUS305
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.
A. Camm (2012)
10.1056/NEJMoa0805796
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
R. L. Frye (2009)
10.1177/1479164111431470
Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: Results from the DIAD study
S. Tandon (2012)
10.2337/dc17-2352
Characteristics and Prognosis in Women and Men With Type 1 Diabetes Undergoing Coronary Angiography: A Nationwide Registry Report
V. Ritsinger (2018)
10.1007/s00125-011-2253-y
Oral glucose tolerance test and HbA1c for diagnosis of diabetes in patients undergoing coronary angiography the Silent Diabetes Study
R. Doerr (2011)
10.1111/jdi.12403
Usefulness of carotid plaque (sum and maximum of plaque thickness) in combination with intima‐media thickness for the detection of coronary artery disease in asymptomatic patients with diabetes
S. Akazawa (2016)
10.1001/jamacardio.2017.2895
Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis: A Systematic Review and Meta-analysis
D. Giacoppo (2017)
Reappraisal of Europeanguidelines on hypertension management: a EuropeanSociety of Hypertension
G Mancia (2009)
Egypt: Egyptian Society of Cardiology, Hosam Hasan-Ali; Estonia: Estonian Society of Cardiology
Denmark
Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
B Pitt (1999)
NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial
K B Margulies (2016)
Use of Ggycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation
10.1056/NEJMoa0904327
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
L. Wallentin (2009)
The impactof gender and general risk factors on the occurrence of atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus
TJ Orchard (1996)
10.1056/NEJMoa1001121
Effect of valsartan on the incidence of diabetes and cardiovascular events.
J. McMurray (2010)
10.1056/NEJMOA1812389
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Declare–Timi Investigators (2019)
10.1016/S0140-6736(19)31149-3
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
H. Gerstein (2019)
10.1097/00132586-200006000-00059
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
B. Pitt (2000)
10.1378/chest.10-0134
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
R. Pisters (2010)
10.1056/NEJMOA0706628
Effects of torcetrapib in patients at high risk for coronary events.
P. Barter (2007)
10.1161/01.CIR.0000065223.21530.11
Prospective Study of Sudden Cardiac Death Among Women in the United States
C. Albert (2003)
10.2337/dc12-1444
Comment on: Hanssen et al. Associations Between the Ankle-Brachial Index and Cardiovascular and All-Cause Mortality Are Similar in Individuals Without and With Type 2 Diabetes: Nineteen-Year Follow-Up of a Population-Based Cohort Study. Diabetes Care 2012;35:1731–1735
I. Tasci (2013)
10.1111/j.1464-5491.2004.01255.x
A 14‐year prospective study of autonomic nerve function in Type 1 diabetic patients: association with nephropathy
A. Forsén (2004)
10.1007/s00125-010-1806-9
Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes
M. Taskinen (2010)
10.1002/ejhf.347
Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial
M. Komajda (2015)
10.1056/NEJM199909023411001
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
B. Pitt (1999)
10.1210/jc.2008-0222
Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline.
J. Rosenzweig (2008)
10.1161/01.CIR.96.7.2455
Incidence of and risk factors for atrial fibrillation in older adults.
B. Psaty (1997)
10.1097/HJH.0b013e328310e0d9
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes
J. Östergren (2008)
10.1016/S0002-8703(03)00415-0
Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
G. Fragasso (2003)
10.1007/s40279-018-0930-4
Exercise Prescription in Patients with Different Combinations of Cardiovascular Disease Risk Factors: A Consensus Statement from the EXPERT Working Group
D. Hansen (2018)
10.2337/dc10-2414
Postprandial Blood Glucose Predicts Cardiovascular Events and All-Cause Mortality in Type 2 Diabetes in a 14-Year Follow-Up
F. Cavalot (2011)
10.1016/S0140-6736(02)09895-1
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial
K. Dickstein (2002)
10.2337/DIACARE.26.3.725
The diabetes risk score: a practical tool to predict type 2 diabetes risk.
J. Lindström (2003)
10.1007/s00125-006-0435-9
Coffee consumption and risk of total and cardiovascular mortality among patients with type 2 diabetes
S. Bidel (2006)
10.2337/DIACARE.28.5.1158
Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic type 2 diabetic subjects.
S. Bernard (2005)
10.1016/J.AMJHYPER.2004.11.038
The association of heart failure with insulin resistance and the development of type 2 diabetes.
J. Kostis (2005)
10.1007/s00125-016-4157-3
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
V. Vallon (2016)
10.1177/1741826710394270
Contemporary model for cardiovascular risk prediction in people with type 2 diabetes
A. Kengne (2011)
10.1016/S0735-1097(03)00262-6
Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.
P. Shekelle (2003)
10.1056/NEJMRA000650
Sudden death due to cardiac arrhythmias.
H. Huikuri (2001)
10.1016/S0140-6736(10)60234-6
Balancing the benefits of statins versus a new risk—diabetes
C. Cannon (2010)
10.1097/HJH.0b013e32831e13e5
Mechanisms of hypertension in the cardiometabolic syndrome
Josep Redon (2009)
10.1177/2047487318807767
Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction
A. Pavlović (2019)
10.1161/CIRCULATIONAHA.111.019745
Antiplatelet Therapy and Proton Pump Inhibition: Clinician Update
G. Moukarbel (2012)
10.1016/j.amjmed.2011.07.027
Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes.
C. Lin (2012)
10.1002/cpt.705
Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development
T. Hwang (2017)
10.1161/CIRCULATIONAHA.119.041840
Letter by Wang and Xu Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks".
J. Wang (2019)
Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly
L Amato (1997)
10.1016/S2213-8587(14)70057-9
Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.
G. Li (2014)
10.2337/dc10-0939
The Influence of Glycemic Control on the Prognosis of Japanese Patients Undergoing Percutaneous Transluminal Angioplasty for Critical Limb Ischemia
M. Takahara (2010)
10.1161/01.STR.25.1.40
Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study.
R. D'Agostino (1994)
The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003;26:1895–1901
RE Maser (1901)
40 9.2.1 Ventricular premature beats and paroxysmal ventricular tachycardia
. . . . . Ventricular
Zeiher AM; Odyssey Outcomes Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome
G G Schwartz (2018)
10.1093/eurheartj/ehv008
Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV--a survey from the European Society of Cardiology.
V. Gyberg (2015)
10.1136/bmj.321.7258.405
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
I. Stratton (2000)
10.1016/0735-1097(95)00126-K
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year.
K. Malmberg (1995)
10.1093/EURHEARTJ/EHI230
Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events.
A. Svensson (2005)
10.1093/EUROPACE/EUW295
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
P. Kirchhof (2016)
10.1038/414799a
Insulin signalling and the regulation of glucose and lipid metabolism
A. Saltiel (2001)
10.2174/138920011794520053
Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
M. Abe (2011)
10.2337/DIABETES.51.12.3524
Lower heart rate variability is associated with the development of coronary heart disease in individuals with diabetes: the atherosclerosis risk in communities (ARIC) study.
D. Liao (2002)
10.1054/JCAF.2003.31
Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers.
M. Bobbio (2003)
10.1001/jama.2008.623
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
H. Ogawa (2008)
10.1161/01.STR.0000260100.71665.2f
Incidence and Risk Factors for Stroke in Type 2 Diabetic Patients: The DAI Study
C. Giorda (2007)
10.1093/ejechocard/jep007
Recommendations for the evaluation of left ventricular diastolic function by echocardiography.
S. Nagueh (2009)
10.1097/HJR.0b013e3283294b1d
EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries
K. Kotseva (2009)
10.2337/dc09-0831
Long-Term Outcomes of Diabetic Patients With Critical Limb Ischemia Followed in a Tertiary Referral Diabetic Foot Clinic
L. Uccioli (2010)
10.1136/bmjdrc-2016-000354
Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes
O. Snorgaard (2017)
10.1007/s11883-014-0457-6
Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
C. Johnston (2014)
10.1016/S0140-6736(18)31924-X
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
J. Gaziano (2018)
10.1016/j.jacc.2013.05.069
PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial.
M. Hülsmann (2013)
ESC / EACTS Guidelines on Myocardial Revascularisation
S. Achenbach (2012)
10.1002/ejhf.600
Reframing the association and significance of co‐morbidities in heart failure
F. Triposkiadis (2016)
10.1056/NEJMoa1208799
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Hans‐Henrik Parving (2012)
10.2337/DIACARE.26.10.2770
Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes.
A. Tenerz (2003)
10.1016/J.AHJ.2004.05.056
Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.
P. Deedwania (2005)
10.1001/JAMA.295.3.306
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
J. Berger (2006)
10.1016/J.AHJ.2004.07.027
Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study.
E. Faglia (2005)
10.1007/s00125-009-1470-0
Intensive glucose control and macrovascular outcomes in type 2 diabetes
F. Turnbull (2009)
10.1016/j.jvs.2008.06.005
The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in diabetic and nondiabetic subjects.
V. Aboyans (2008)
10.1136/bmj.a1840
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
J. Belch (2008)
10.1016/S0140-6736(09)61457-4
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
W. Knowler (2009)
Associations Between the Ankle- Brachial Index and Cardiovascular and All-CauseMortality Are Similar in IndividualsWithout andWith Type 2 Diabetes Nineteen-year follow-up of a population-based cohort study
Nordin (2012)
10.1136/bmj.b4909
The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study
D. Bonds (2010)
The longterm effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study
G Li (2008)
[The Framingham function overestimates stroke risk for diabetes and metabolic syndrome among Spanish population].
B. Costa (2005)
10.1016/S0002-8703(03)00403-4
Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.
S. Haas (2003)
10.1056/NEJMoa1509225
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
M. Pfeffer (2015)
10.1161/ATVBAHA.111.241869
Metabolic Syndrome, Insulin Resistance, and Roles of Inflammation – Mechanisms and Therapeutic Targets
G. Romeo (2012)
10.1111/dme.12232
Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis
O. Phung (2013)
10.1111/j.1463-1326.2011.01383.x
Lipid‐altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials
Lawrence A Leiter (2011)
10.1002/14651858.CD005449.pub2
Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.
N. Valentine (2012)
10.1161/CIR.0b013e318276fbcb
Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association.
V. Aboyans (2012)
10.2337/dc10-1206
Glycemic Thresholds for Diabetes-Specific Retinopathy
S. Colagiuri (2010)
10.1097/HJH.0000000000001276
Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials
C. Thomopoulos (2017)
10.1161/CIRCULATIONAHA.112.147488
Cost-Effectiveness of Percutaneous Coronary Intervention With Drug Eluting Stents Versus Bypass Surgery for Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease: Results From the FREEDOM Trial
Elizabeth A. Magnuson (2013)
10.1161/CIRCULATIONAHA.118.038352
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
C. Investigators (2019)
10.1007/s00125-009-1454-0
Cardiovascular risk assessment scores for people with diabetes: a systematic review
P. Chamnan (2009)
10.1016/j.cpcardiol.2010.10.001
Multimodality imaging in diabetic heart disease.
A. Ng (2011)
10.1016/S0002-9149(00)00920-6
Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study).
J. Singh (2000)
10.1161/01.CIR.0000035653.72855.BF
Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study
M. Packer (2002)
10.1161/CIRCULATIONAHA.105.562421
Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial
M. Sabaté (2005)
10.1093/ckj/sfy090
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
W. Herrington (2018)
10.1161/01.ATV.17.4.802
Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis.
A. S. Brown (1997)
10.1016/S0140-6736(10)61198-1
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
K. Swedberg (2010)
10.1136/bmj.h1035
Statins and congenital malformations: cohort study
B. Bateman (2015)
10.1007/s10557-017-6754-x
Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes
S. L. Kristensen (2017)
10.1136/bmjopen-2015-010055
Has the difference in mortality between percutaneous coronary intervention and coronary artery bypass grafting in people with heart disease and diabetes changed over the years? A systematic review and meta-regression
P. Herbison (2015)
10.1016/S0140-6736(10)61350-5
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaborati (2010)
10.1001/ARCHINTE.165.12.1401
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
P. Whelton (2005)
10.1160/THS10-11-0739
Inflammation and thrombosis in diabetes.
K. Hess (2011)
10.1161/CIRCULATIONAHA.107.706416
Inadequate Blood Glucose Control Is Associated With In-Hospital Mortality and Morbidity in Diabetic and Nondiabetic Patients Undergoing Cardiac Surgery
R. Ascione (2008)
10.1016/S0140-6736(02)08090-X
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
L. Lindholm (2002)
10.1056/NEJMOA052187
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
D. Nathan (2005)
10.1186/1745-6215-15-321
Effect of guided self-determination youth intervention integrated into outpatient visits versus treatment as usual on glycemic control and life skills: a randomized clinical trial in adolescents with type 1 diabetes
G. R. Husted (2014)
10.1056/NEJM198911233212103
The effect on serum cholesterol levels of coffee brewed by filtering or boiling.
A. Bak (1989)
10.1056/NEJMOA021778
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
Peter A. Gaede (2003)
10.1016/S0140-6736(03)13636-7
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
R. Collins (2003)
10.1016/S0140-6736(03)14338-3
Estimates of global mortality attributable to smoking in 2000
M. Ezzati (2003)
10.1186/1471-2458-8-423
High prevalence of obesity, central obesity and abnormal glucose tolerance in the middle-aged Finnish population
T. Saaristo (2008)
10.1056/NEJMoa1601895
Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure
M. Packer (2017)
10.2337/dc10-2375
Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia
I. Raz (2011)
10.1016/j.ahj.2012.06.008
Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease.
Jean-Guillaume Dillinger (2012)
10.1016/j.atherosclerosis.2013.01.011
Incremental prognostic value of stress myocardial perfusion imaging in asymptomatic diabetic patients.
W. Acampa (2013)
10.1161/HYPERTENSIONAHA.111.189589
Differential Effects of Nebivolol and Metoprolol on Insulin Sensitivity and Plasminogen Activator Inhibitor in the Metabolic Syndrome
K. Ayers (2012)
10.1161/CIR.0000000000000510
Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association
F. Sacks (2017)
10.2215/CJN.02870316
Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study.
I. D. de Boer (2016)
[Variability in the calculation of coronary risk in type-2 diabetes mellitus].
J. Jimeno Mollet (2005)
10.1016/j.amjcard.2009.08.642
Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus.
J. Borer (2010)
10.2337/dc10-0125
Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
R. Pop-Busui (2010)
10.1007/s00125-004-1574-5
Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study
B. Balkau (2004)
10.1056/NEJM199309303291401
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long‐Term Complications in Insulin‐Dependent Diabetes Mellitus
D. Nathan (1993)
10.1161/01.CIR.96.1.25
High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells.
F. Cosentino (1997)
10.1016/j.jdiacomp.2015.08.011
Abdominal aortic aneurysms and diabetes mellitus.
K. Pafili (2015)
10.1016/J.JCLINEPI.2003.10.007
Two prospective studies found that elevated 2-hr glucose predicted male mortality independent of fasting glucose and HbA1c.
Q. Qiao (2004)
10.1016/S0140-6736(02)09089-X
Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study
A. Norhammar (2002)
10.1016/J.ATHORACSUR.2004.02.038
Comparison of bilateral thoracic artery grafting with percutaneous coronary interventions in diabetic patients.
C. Locker (2004)
10.14341/2071-8713-5281
Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Forceon Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World HeartFederation; International Atherosclerosis Society; and International Asso
G. AlbertiK (2010)
10.1056/NEJMOA1801174
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Odyssey Outcomes Investigators (2018)
10.1093/EURHEARTJ/EHM518
The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
L. Mellbin (2008)
10.2337/dc07-S048
Nutrition Recommendations and Interventions for Diabetes
(2007)
MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION
teven (2000)
10.1093/eurheartj/ehz425
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.
J. Knuuti (2019)
10.1053/j.ajkd.2015.12.015
US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States.
(2016)
Treatment potential for cholesterol management in patients with coronary heart disease in15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis
K Kotseva (2008)
10.1136/bmj.39106.476215.BE
Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery
O. Aziz (2007)
Ong TK; BEST Trial Investigators. Trial of everolimuseluting stents or bypass surgery for coronary disease
S J Park (2015)
Taggart DP; RADIAL Investigators. Radialartery or saphenous-vein grafts in coronary-artery bypass surgery
M Gaudino (2018)
Buse JB; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes
Jfe Mann (2017)
Mohr FW; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease
P W Serruys (2009)
10.1161/CIRCRESAHA.116.305697
Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.
J. Hall (2015)
10.1016/S0140-6736(98)07019-6
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
UK Prospective Diabetes Study Group (1998)
10.1016/S2213-8587(19)30158-5
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Odyssey Outcomes Investigators (2019)
10.1136/bmj.a1331
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis
C. Stettler (2008)
10.1016/S0140-6736(05)67528-9
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
J. Dormandy (2005)
10.2337/dc11-0480
Cardiovascular Risk Prediction Is Improved by Adding Asymptomatic Coronary Status to Routine Risk Assessment in Type 2 Diabetic Patients
E. Cosson (2011)
10.1210/jc.2008-1824
Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?
A. Ceriello (2009)
10.1186/1741-7015-4-22
Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications
S. Hernández-Díaz (2006)
10.2337/DIACARE.28.11.2722
Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study.
P. Valensi (2005)
10.1016/j.athoracsur.2012.11.068
Bilateral internal thoracic artery harvest and deep sternal wound infection in diabetic patients.
Salil V. Deo (2013)
Beta-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease
E. V. Simon (2013)
10.1016/j.rec.2011.09.015
ESC/EAS Guidelines for the management of dyslipidaemias
Ž. Reiner (2017)
10.1016/S2213-8587(17)30313-3
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
M. Sabatine (2017)
10.1016/S2213-8587(18)30136-0
Glycaemic variability in diabetes: clinical and therapeutic implications.
A. Ceriello (2019)
10.1016/j.jacc.2009.03.032
Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis.
H. Thiele (2009)
10.1016/j.jacc.2010.02.046
Cardiovascular events during differing hypertension therapies in patients with diabetes.
M. Weber (2010)
10.2337/DIACARE.22.11.1827
Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients.
A. Norhammar (1999)
10.1007/s00125-010-1918-2
HbA1c and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study
R. Borg (2010)
10.1093/eurheartj/ehy066
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis.
B. Rocca (2018)
10.1016/j.jvs.2015.12.041
Impact of diabetes on carotid artery revascularization.
M. Hussain (2016)
10.1002/dmrr.2625
Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta‐analysis
F. Zaccardi (2015)
10.2337/DIACARE.22.7.1186
Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes.
T. Berg (1999)
10.1038/nrendo.2010.122
Effect of systemic medications on onset and progression of diabetic retinopathy
P. Silva (2010)
10.1007/s00125-010-1718-8
Association of glucose metabolism with diastolic function along the diabetic continuum
R. Stahrenberg (2010)
10.1111/j.1538-7836.2004.00836.x
Platelet activation in type 2 diabetes mellitus
P. Ferroni (2004)
10.1016/J.AHJ.2005.09.015
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.
C. Stettler (2006)
10.1177/1479164117744490
An analysis of barriers to entry of cardiac rehabilitation in patients with diabetes: Using data from the National Audit of Cardiac Rehabilitation
A. Harrison (2018)
10.2337/dc17-2530
Risk of Cardiovascular Disease and Death in Individuals With Prediabetes Defined by Different Criteria: The Whitehall II Study
D. Vistisen (2018)
10.1007/s12020-015-0775-7
The role of patient education in the prevention and management of type 2 diabetes: an overview
A. Coppola (2015)
10.1001/jama.2016.17020
Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women: A Meta-analysis.
M. Kavousi (2016)
10.1016/j.jacc.2009.12.003
The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study.
Aaron M. From (2010)
10.1093/eurheartj/eht296
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
G. Montalescot (2013)
10.1016/S0140-6736(12)60367-5
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
B. Mihaylova (2012)
10.1517/17425255.2013.777428
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
A. Scheen (2013)
10.2337/dc10-0247
Evolution of Percutaneous Coronary Intervention in Patients with Diabetes
J. Rana (2010)
10.1111/j.1742-1241.2007.01606.x
The team approach to diabetes management: partnering with patients
P. Aschner (2007)
10.1161/ATVBAHA.107.160192
Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome
M. Adiels (2008)
10.2337/dc07-0717
Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease
E. Erdmann (2007)
10.1056/NEJM200105033441801
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
J. Tuomilehto (2001)
10.1161/CIRCULATIONAHA.107.697979
Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection.
R. Kloner (2008)
10.1161/CIR.0000000000000579
Health Literacy and Cardiovascular Disease: Fundamental Relevance to Primary and Secondary Prevention: A Scientific Statement From the American Heart Association.
J. Magnani (2018)
10.1373/clinchem.2008.111401
Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
V. Charlton-Menys (2009)
10.1016/j.ophtha.2008.10.016
The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes.
R. Klein (2009)
10.1093/eurheartj/ehr373
Antiplatelet agents for the treatment and prevention of atherothrombosis.
C. Patrono (2011)
10.1016/j.ahj.2015.12.015
High-sensitive troponin T is associated with all-cause and cardiovascular mortality in stable outpatients with type 2 diabetes (ZODIAC-37).
S. H. Hendriks (2016)
Prediction of mortality using measures of cardiacautonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care 2008;31:556–561
D Ziegler (2008)
D’AgostinoRBSr., WilsonPW.Fasting andpostchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;25:1845–1850
JB Meigs (2002)
Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes
S D Wiviott (2007)
Massaro JM; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
L Mauri (2014)
2.1 Percutaneous coronary intervention vs. coronary artery bypass graft surgery
10.1016/S0140-6736(18)30309-X
Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial
R. McManus (2018)
Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a crosssectional study
W Dinh (2010)
10.1016/j.kint.2017.04.018
Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.
Julie Galsgaard (2017)
10.1093/eurheartj/ehy686
Corrigendum to: 2018 ESC/ESH Guidelines for the management of arterial hypertension.
(2019)
10.2337/dc11-2216
Macronutrients, Food Groups, and Eating Patterns in the Management of Diabetes
M. Wheeler (2012)
10.1161/CIRCULATIONAHA.108.816694
Predicting the 30-Year Risk of Cardiovascular Disease: The Framingham Heart Study
M. Pencina (2009)
10.1136/bmj.38678.389583.7C
Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies
R. Huxley (2005)
10.1161/HS1101.098524
Risk Factors, Outcome, and Treatment in Subtypes of Ischemic Stroke: The German Stroke Data Bank
A. Grau (2001)
10.1007/s00125-016-3956-x
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
N. Sattar (2016)
10.1093/EURHEARTJ/EHM161
[Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes].
J. Bassand (2008)
10.1016/S0140-6736(17)32458-3
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
S. Connolly (2018)
10.1111/dom.13348
Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: A systematic review and meta‐analysis
C. Fitzpatrick (2018)
10.1111/j.1463-1326.2010.01349.x
Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomized clinical trials
C. Lamanna (2011)
10.1056/NEJMoa1804988
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
L. Bowman (2018)
Zimmet P; Residual Risk Reduction Initiative. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient
J C Fruchart (2008)
Diabetes and risk of stroke in atrial fibrillation
10.1056/NEJMoa0804748
Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates.
F. Sacks (2009)
10.1161/JAHA.116.005156
Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post‐Hoc Analysis of the GISSI‐HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca‐Heart Failure) Trial
M. Dauriz (2017)
10.1056/NEJMoa1305889
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
W. White (2013)
10.7326/M15-2650
Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes
Nisa M. Maruthur (2016)
Diabetic retinopathy. Diabetes Care 2003;26:226–229
DS Fong (2003)
Kappetein AP; EXCEL Trial Investigators. Everolimus-eluting stents or bypass surgery for left main coronary artery disease
G W Stone (2016)
10.1093/eurheartj/ehn156
Diabetes, left ventricular systolic dysfunction, and chronic heart failure.
M. R. Macdonald (2008)
10.1001/ARCHINTE.161.7.996
Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study.
J. He (2001)
10.2337/dc10-S062
Diagnosis and Classification of Diabetes Mellitus
P. O S I T I O N S T A T E M E N T (2010)
Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.
D. Giugliano (1997)
10.1016/S0140-6736(03)14284-5
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
C. Granger (2003)
10.1001/jama.2011.860
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
D. Preiss (2011)
10.1016/S0140-6736(12)60441-3
Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data
M. Lorenz (2012)
10.1161/CIRCHEARTFAILURE.112.000162
Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure: Systematic Review of Observational Studies Involving 34 000 Patients
D. Eurich (2013)
10.1016/j.jacc.2016.06.024
Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease.
R. Cavalcante (2016)
10.1016/S0749-4041(10)79320-9
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
G. Moneta (2010)
10.1056/NEJMoa1812792
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt (2019)
10.1016/j.jand.2015.02.031
Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials.
M. Franz (2015)
10.1016/S0140-6736(08)60868-5
Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial
D. Wood (2008)
10.2337/dc06-2626
Effects of Different Modes of Exercise Training on Glucose Control and Risk Factors for Complications in Type 2 Diabetic Patients: a Meta-Analysis
N. Snowling (2007)
10.1016/j.acvd.2010.11.013
Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature.
P. Valensi (2011)
10.1016/J.JACC.2005.05.051
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
H. Abuissa (2005)
10.1016/J.JACC.2006.04.070
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.
C. Cannon (2006)
10.1016/j.diabet.2013.02.006
Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes.
A. Scheen (2013)
10.1186/1475-2840-9-63
Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study
W. Dinh (2010)
10.1111/j.1464-5491.2004.01157.x
Detecting silent coronary stenoses and stratifying cardiac risk in patients with diabetes: ECG stress test or exercise myocardial scintigraphy?
E. Cosson (2004)
10.1111/dom.12821
Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta‐analysis of survival data
S. Bain (2017)
10.1111/j.1464-5491.2007.02190.x
Physical activity consultation for people with Type 2 diabetes. Evidence and guidelines
A. Kirk (2007)
10.1055/s-0029-1240928
A European evidence-based guideline for the prevention of type 2 diabetes.
B. Paulweber (2010)
10.1177/2047487315599892
Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study
J. Pallisgaard (2016)
10.1155/2017/8493145
The Effectiveness of Lifestyle Adaptation for the Prevention of Prediabetes in Adults: A Systematic Review
George Kerrison (2017)
10.1002/ejhf.813
Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry
O. Chioncel (2017)
10.2337/DIACARE.26.10.2791
Diabetes and idiopathic cardiomyopathy: a nationwide case-control study.
A. Bertoni (2003)
10.1177/1358836X0100600i102
Peripheral arterial disease - epidemiological aspects
M. Criqui (2001)
10.1056/NEJMoa1500857
Long-term use of ticagrelor in patients with prior myocardial infarction.
Marc P. Bonaca (2015)
10.1016/S0140-6736(18)30423-9
Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data
S. Head (2018)
10.1016/S0140-6736(18)31133-4
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials
P. Rothwell (2018)
10.1016/S2213-8587(19)30068-3
Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial.
M. Lean (2019)
10.1016/J.JACC.2006.12.048
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
E. Erdmann (2007)
10.1016/j.ahj.2014.06.023
Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction.
Suzanne V Arnold (2014)
10.1002/DMRR.2625
Mean Platelet Volume, Platelet Distribution Width, and Platelet Count in Type 2 Diabetes Mellitus, Impaired Fasting Glucose, and Metabolic Syndrome: systematic review and meta-analysis
F. Zaccardi (2014)
10.1097/00008483-200105000-00012
EFFECTS ON BLOOD PRESSURE OF REDUCED DIETARY SODIUM AND THE DIETARY APPROACHES TO STOP HYPERTENSION ( DASH ) DIET
Rank (2000)
10.1016/j.jacc.2008.03.051
Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials.
S. Nicholls (2008)
10.1016/j.atherosclerosis.2017.07.009
Comparison of non-traditional biomarkers, and combinations of biomarkers, for vascular risk prediction in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study
Anna H. Price (2017)
10.1111/j.1464-5491.2012.03759.x
Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial
R. K. Simmons (2012)
10.1586/erc.09.133
Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus
G. Reboldi (2009)
10.1053/EJVS.1999.1006
Long-term results following operation for diabetic foot problems: arterial disease confers a poor prognosis.
W. Campbell (2000)
10.1161/HYPERTENSIONAHA.117.09259
Risk of Cardiovascular Events in Patients With Diabetes Mellitus on β-Blockers
T. Tsujimoto (2017)
10.1016/j.ijcard.2010.08.037
Effects of high dose aleglitazar on renal function in patients with type 2 diabetes.
M. Herz (2011)
10.1007/s00125-009-1457-x
Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial
J. Beulens (2009)
10.1001/ARCHINTE.166.13.1368
An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study.
A. Folsom (2006)
10.1046/J.1523-1755.2003.00712.X
Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).
A. Adler (2003)
10.1056/NEJMoa0802743
Effects of intensive glucose lowering in type 2 diabetes.
H. Gerstein (2008)
10.1093/oxfordjournals.qjmed.a067610
The natural history of diabetic autonomic neuropathy.
D. Ewing (1980)
10.1016/S0140-6736(09)60443-8
Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study
R. Schnabel (2009)
10.1001/JAMA.298.22.2654
Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis.
C. Willi (2007)
10.1007/BF03346265
QT interval, cardiovascular risk factors and risk of death in diabetes
M. Veglio (2004)
10.1056/NEJMOA0706482
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
S. Wiviott (2007)
10.1056/NEJMoa1206797
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
G. Schwartz (2012)
Bain SC; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes
M Husain
EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
B Zinman (2015)
EMPA-REG OUTCOME V R trial investigacardiovascular risk: results of the EMPA-REG OUTCOME V R trial
D Fitchett (2016)
10.1160/TH07-08-0508
Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data.
M. Hughes (2008)
RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
P D Home (2009)
Oral glucose tolerance test and HbA 1 c for diagnosis of diabetes in patients undergoing coronary angiography: [corrected] the Silent Diabetes Study
R Doerr (2011)
10.1161/CIRCINTERVENTIONS.111.963512
Impact of Completeness of Revascularization on Long-Term Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D)
L. Schwartz (2012)
10.1016/S0140-6736(18)30134-X
Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies
A. Wood (2018)
10.2337/dc14-1329
Predictors of Nonsevere and Severe Hypoglycemia During Glucose-Lowering Treatment With Insulin Glargine or Standard Drugs in the ORIGIN Trial
Origin Trial Investigators (2014)
10.1001/jama.2010.1710
Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial.
T. Church (2010)
10.1016/j.ijcard.2012.01.052
Predictors of diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes.
Jelena P. Seferović Mitrović (2012)
10.1161/CIRCULATIONAHA.107.740498
Glucometrics in Patients Hospitalized With Acute Myocardial Infarction: Defining the Optimal Outcomes-Based Measure of Risk
M. Kosiborod (2008)
10.2217/cer-2017-0011
Effectiveness and safety of anti-ischemic trimetazidine in patients with stable angina pectoris and Type 2 diabetes.
Z. Meiszterics (2017)
10.1016/S0140-6736(03)14282-1
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
M. Pfeffer (2003)
10.5603/KP.2016.0120
[2016 European Guidelines on cardiovascular disease prevention in clinical practice].
M. Piepoli (2016)
Impact of hypoglycaemia on coronary artery disease and hypertension.
M. Fisher (2002)
10.2337/dc13-1544
Effect of Early Multifactorial Therapy Compared With Routine Care on Microvascular Outcomes at 5 Years in People With Screen-Detected Diabetes: A Randomized Controlled Trial
A. Sandbæk (2014)
10.2337/dc17-1144
The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study)
N. Laiteerapong (2018)
10.1056/NEJMOA032292
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
M. Pfeffer (2003)
10.1161/CIRCULATIONAHA.114.014796
Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry
M. Cavender (2015)
10.1007/s11892-017-0942-8
Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions
A. Chait (2017)
10.2337/db14-0930
Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients With Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC
J. Lachin (2014)
10.1016/S0140-6736(17)33102-1
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
M. Lean (2018)
10.1056/NEJMP068177
Obesity and diabetes in the developing world--a growing challenge.
Parvez Hossain (2007)
10.1016/j.amjmed.2008.09.038
Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.
D. Wald (2009)
10.1002/hep.23280
Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications
E. Fabbrini (2010)
10.1161/CIRCULATIONAHA.112.000646
Bayesian Methods Affirm the Use of Percutaneous Coronary Intervention to Improve Survival in Patients With Unprotected Left Main Coronary Artery Disease
J. A. Bittl (2013)
10.1111/j.1753-0407.2010.00069.x
Lifestyle factors and mortality among adults with diabetes: findings from the European Prospective Investigation into Cancer and Nutrition–Potsdam study *
U. Noethlings (2010)
10.1016/S0735-1097(00)00582-9
Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study.
J. Gottdiener (2000)
10.1016/S0140-6736(06)68845-4
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
S. Connolly (2006)
10.1056/NEJMoa0806359
Long-term follow-up after tight control of blood pressure in type 2 diabetes.
R. Holman (2008)
10.1586/erc.11.196
Statin use during pregnancy: a systematic review and meta-analysis
D. M. Kusters (2012)
10.1210/jc.2010-0449
Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction.
M. Zeller (2010)
10.1136/bmjdrc-2017-000438
Statin use and risk of developing diabetes: results from the Diabetes Prevention Program
J. Crandall (2017)
10.1016/S2213-8587(17)30317-0
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
O. Vaccaro (2017)
10.2337/dc16-2016
Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry
M. Dauriz (2017)
10.1001/jama.2019.13772
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
J. Rosenstock (2019)
10.1161/01.CIR.0000089189.70578.E2
Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part II
T. Lüscher (2003)
10.1016/S0140-6736(12)60367-5
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaborato (2012)
10.1161/JAHA.117.006404
Benefits of Cardiac Rehabilitation on Cardiovascular Outcomes in Patients With Diabetes Mellitus After Percutaneous Coronary Intervention
M. Jiménez-Navarro (2017)
10.2337/dc08-1671
Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial
I. Raz (2009)
10.1016/S0735-1097(01)01230-X
The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study.
J. Liu (2001)
Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study
(2015)
Council on Cardiovascular Surgery and Anesthesia. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association
(2012)
American Heart Association Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Peripheral Vascular Disease
J W Magnani
10.1016/j.amjcard.2009.06.063
Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus.
A. Ng (2009)
10.1016/S0738-3991(98)90096-9
Patient-centred medicine: Transforming the clinical method
J. Brown (1995)
10.1056/NEJMoa1107477
C-reactive protein, fibrinogen, and cardiovascular disease prediction.
S. Kaptoge (2012)
10.1056/nejmoa010746
EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION
P. R. R. Ecurrent (2001)
[Coronary risk estimation in Spain using a calibrated Framingham function].
J. Marrugat (2003)
10.1056/NEJMoa0801317
Telmisartan, ramipril, or both in patients at high risk for vascular events.
S. Yusuf (2008)
Action to Control Cardiovascular Risk in Diabetes
M. Özkaya (2013)
10.1007/s00125-010-1948-9
Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study
Q. Gong (2010)
10.1053/EUHJ.2000.2311
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.
L. Rydén (2000)
10.1093/eurheartj/ehn334
NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus.
M. Hülsmann (2008)
10.1016/j.mayocp.2017.11.019
Risk of All‐Cause Mortality in Diabetic Patients Taking &bgr;‐Blockers
T. Tsujimoto (2018)
10.1093/ejcts/ezt017
Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial.
A. Kappetein (2013)
10.1016/j.jcin.2008.07.001
Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery.
J. Kapoor (2008)
10.1007/s00125-012-2534-0
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
S. Inzucchi (2012)
10.1111/dom.12829
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial
B. Neal (2017)
10.1093/EURHEARTJ/EHW110
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
N. Marx (2016)
10.1016/S0140-6736(07)61303-8
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
A. Patel (2007)
10.1016/j.jcin.2009.07.010
Impact of diabetes mellitus on the treatment effect of percutaneous or surgical revascularization for patients with unprotected left main coronary artery disease: a subgroup analysis of the MAIN-COMPARE study.
Won-Jang Kim (2009)
10.1001/jama.2009.496
Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction.
M. Kosiborod (2009)
10.1097/01.hjr.0000136418.47640.bc
Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory?
J. Stephens (2004)
10.2337/DIACARE.27.3.699
Heart failure prevalence, incidence, and mortality in the elderly with diabetes.
A. Bertoni (2004)
10.2337/DIACARE.27.12.2898
Gender difference in the impact of type 2 diabetes on coronary heart disease risk.
A. Juutilainen (2004)
10.1056/NEJMOA1607141
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
S. Marso (2016)
10.1002/14651858.CD003267.pub2
Interventions for providers to promote a patient-centred approach in clinical consultations.
F. Dwamena (2012)
10.1093/EURHEARTJ/EHI808
Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy.
D. V. Anand (2006)
10.1016/J.AMJCARD.2005.07.061
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
A. Carr (2005)
10.1056/NEJMOA012512
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
W. Knowler (2002)
10.2337/DIACARE.24.9.1614
Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors.
G. Nichols (2001)
10.1002/ejhf.679
In‐hospital and 1‐year mortality associated with diabetes in patients with acute heart failure: results from the ESC‐HFA Heart Failure Long‐Term Registry
G. Targher (2017)
10.1093/eurheartj/ehp097
COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment.
F. Pulcinelli (2009)
The Global Burden of Disease Study
C. Murray (2003)
10.1186/s12933-015-0296-y
Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology
V. Gyberg (2015)
10.1093/eurheartj/ehr158
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
Ž. Reiner (2011)
10.1016/J.REC.2011.11.007
ESC Guidelines on the Diagnosis and Treatment of Peripheral Artery Diseases
M. Tendera (2012)
10.1161/CIRCULATIONAHA.118.038352
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
Darren K Mcguire (2019)
10.1093/eurheartj/eht332
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial.
L. Mellbin (2013)
10.1016/j.athoracsur.2011.06.028
Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome.
M. Mack (2011)
10.1016/J.CARDFAIL.2006.08.211
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.
George Sokos (2006)
10.1016/S0140-6736(18)32590-X
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker (2019)
10.2337/DIACARE.22.2.233
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.
M. Coutinho (1999)
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
R. Turner (1998)
10.1002/14651858.cd002967.pub3
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
S. Salpeter (2003)
10.1097/HJR.0b013e3282f335d0
Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart
M. Anselmino (2008)
10.1016/S0140-6736(08)60104-X
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
P. Kearney (2008)
10.7326/0003-4819-151-1-200907070-00120
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
R. Bilous (2009)
10.1016/S2213-8587(18)30079-2
Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies
L WG J J X HC D AJ MH DR DA SAE H P R R RR JR M S N Gnatiuc Herrington Halsey Tuomilehto Fang Kim De B (2018)
10.1016/S0140-6736(05)67394-1
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
C. Baigent (2005)
10.1007/s10741-011-9252-4
What strategies are effective for exercise adherence in heart failure? A systematic review of controlled studies
S. Tierney (2011)
10.1016/S0140-6736(98)07037-8
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
UK Prospective Diabetes Study Group (1998)
Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary. Diabetes Care 2010;33:2692–6
SR Colberg (2010)
ESC Guidelines 3087b by gest on Jauary 27, 2015 D ow nladed fom
B Rocca (2012)
Iceland: Icelandic Society of Cardiology
10.1016/S0140-6736(10)60484-9
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
The Emerging Risk Factors Collaboration (2010)
Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a metaanalysis
F G Fowkes (2008)
10.1016/j.jdiacomp.2014.02.008
Prevalence and associations of diabetic retinopathy in a large cohort of prediabetic subjects: the Gutenberg Health Study.
J. Lamparter (2014)
10.1056/nejm199401133300225
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
A. Fournier (1994)
10.1016/j.amjcard.2014.02.010
One-year outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care] Trial).
H. Selker (2014)
10.1089/dia.2008.0063
Web-based collaborative care for type 1 diabetes: a pilot randomized trial.
K. Mccarrier (2009)
10.1371/journal.pone.0018744
Clinical Use and Effectiveness of Lipid Lowering Therapies in Diabetes Mellitus—An Observational Study from the Swedish National Diabetes Register
B. Eliasson (2011)
10.1056/NEJMC1206011#SA2
Comparative effectiveness of revascularization strategies.
M. Habibi (2012)
10.2337/db10-0165
The Association of Hemoglobin A1c With Incident Heart Failure Among People Without Diabetes: The Atherosclerosis Risk in Communities Study
K. Matsushita (2010)
10.1371/journal.pone.0180804
Long-term efficacy and safety of carotid artery stenting versus endarterectomy: A meta-analysis of randomized controlled trials
Y. Li (2017)
10.1177/1479164118794619
Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function
I. Johansson (2018)
10.2337/dc12-1311
Diabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial
H. Gerstein (2013)
10.1016/S0140-6736(99)04383-4
Diabetes as a risk factor for sudden death
B. Balkau (1999)
10.1016/j.diabet.2010.02.004
A large proportion of prediabetes and diabetes goes undiagnosed when only fasting plasma glucose and/or HbA1c are measured in overweight or obese patients.
E. Cosson (2010)
10.1016/j.jacc.2017.05.061
Influence of Diabetes on Long-Term Coronary Artery Bypass Graft Patency.
Sajjad Raza (2017)
10.1002/ejhf.1170
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
P. Seferovic (2018)
10.1093/EURHEARTJ/EHT309.P3137
Pericardial fat volume measured by non-contrast tomography improves risk prediction of subclinical coronary artery disease estimated by coronary artery calcium score and Framinghan risk score
L. Carvalho (2013)
10.1111/j.1365-2796.2012.02532.x
Alcohol consumption and risk of type 2 diabetes in European men and women: influence of beverage type and body sizeThe EPIC–InterAct study
J. W. J. Beulens (2012)
10.1056/nejmc1003829
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.
A. Thanopoulou (2010)
10.1016/J.MCNA.2004.06.001
The global epidemiology of heart failure.
J. Young (2004)
10.1016/S0140-6736(99)08415-9
Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview
S. Capes (2000)
10.1016/S2213-8587(14)70088-9
Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.
V. Ritsinger (2014)
10.1016/j.ijcard.2015.01.017
Silent coronary artery disease and incidence of cardiovascular and mortality events at different levels of glucose regulation; results of greater than a decade follow-up.
F. Hadaegh (2015)
10.1056/NEJMc1112233
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
S. Pearson (2011)
10.1681/ASN.2008121270
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.
T. Ninomiya (2009)
10.7326/M18-0567
Fracture Risk After Initiation of Use of Canagliflozin
M. Fralick (2019)
10.1016/j.ejvs.2009.02.022
The prognostic value of impaired walking distance on long-term outcome in patients with known or suspected peripheral arterial disease.
Inge I de Liefde (2009)
The Task Force on Myocardial Revascularisation of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on myocardial revascularization
W Wijns (2010)
1.1.2 ACCORD, ADVANCE, and
. . . . . . . . . . . . . . . . . . Control
Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
L SjöStröM (2004)
10.1001/archinternmed.2012.3130
Physical Activity and Mortality in Individuals With Diabetes Mellitus: A Prospective Study and Meta-analysis.
D. Sluik (2012)
10.1007/s00125-010-1951-1
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
T. Davis (2010)
10.1016/j.hrthm.2010.07.031
Sudden cardiac death after myocardial infarction in patients with type 2 diabetes.
M. Junttila (2010)
World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate and hyperglycaemia
Fourier Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease
M S Sabatine (2017)
PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction
M P Bonaca (2015)
10.1016/j.ijcard.2016.02.074
Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial.
A. Abdul-Rahim (2016)
10.1056/NEJMOA1410489
Ezetimibe added to statin therapy after acute coronary syndromes
Improve-It Investigators (2015)
Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients.
A. Gottsäter (1993)
10.2337/dc09-1843
Moving to an A1C-Based Diagnosis of Diabetes Has a Different Impact on Prevalence in Different Ethnic Groups
D. L. Christensen (2009)
10.1001/jama.2012.9630
Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis.
H. D. den Ruijter (2012)
10.1161/CIRCULATIONAHA.108.791061
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
S. D. Wiviott (2008)
10.1001/jama.2014.15825
Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial.
J. Muhlestein (2014)
10.1016/j.amjcard.2008.09.067
Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications.
C. Cannon (2008)
10.2337/db06-0653
The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study
P. Cleary (2006)
10.1097/HJH.0b013e3282efc214
Intake of fruit, vegetables, and antioxidants and risk of type 2 diabetes: systematic review and meta-analysis
M. Hamer (2007)
10.1056/NEJMoa1716026
Radial‐Artery or Saphenous‐Vein Grafts in Coronary‐Artery Bypass Surgery
M. Gaudino (2018)
10.1016/S0735-1097(99)00146-1
Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction
I. Gustafsson (1999)
10.1097/00004872-200018110-00020
Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension–2
L. Lindholm (2000)
10.3410/f.717982049.793472489
Faculty of 1000 evaluation for Primary prevention of cardiovascular disease with a Mediterranean diet.
M. Fogelholm (2013)
10.1016/s1388-9842(01)00174-x
Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure.
E. Erdmann (2001)
10.2337/dc17-1600
International Consensus on Use of Continuous Glucose Monitoring
T. Danne (2017)
10.1007/s00125-002-1009-0
The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes
S. Kahn (2003)
10.1046/J.1444-2892.2003.00197.X
CHART: congestive cardiac failure in hospitals, an Australian review of treatment.
J. Wlodarczyk (2003)
10.1016/S2213-8587(15)00291-0
Long-term Effects of Lifestyle Intervention or Metformin on Diabetes Development and Microvascular Complications: the DPP Outcomes Study
D. Nathan (2015)
10.1056/NEJMc1515130
Excess Mortality among Persons with Type 2 Diabetes.
T. Byers (2016)
10.1161/CIRCULATIONAHA.116.024593
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)
S. L. Kristensen (2017)
10.7326/M15-0452
Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force
E. Balk (2015)
10.1016/S2213-8587(17)30087-6
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
J. Seferovic (2017)
10.1097/JCN.0b013e3181cc79be
Randomized Trials of Nursing Interventions for Secondary Prevention in Patients With Coronary Artery Disease and Heart Failure: Systematic Review
J. Allen (2010)
10.1016/j.amjcard.2009.09.041
Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus.
D. Aguilar (2010)
10.1056/NEJMOA032423
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
M. Bristow (2004)
10.1111/dom.13492
Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials
C. Bailey (2019)
10.1016/S1262-3636(10)70470-5
Impaired awareness of hypoglycaemia: a review.
A. Graveling (2010)
10.1002/ejhf.566
European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions
M. Crespo-Leiro (2016)
10.1016/S1388-9842(01)00174-X
Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure
Erdmann Erland (2001)
10.2337/dc07-0048
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
X. Pi-Sunyer (2007)
10.1016/j.diabres.2017.02.021
Systematic review on the cost-effectiveness of self-management education programme for type 2 diabetes mellitus.
J. X. Lian (2017)
10.1056/NEJMoa1001286
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
W. Cushman (2010)
10.1136/bmj.39314.620174.80
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review
D. Eurich (2007)
Definition, diagnosis and classificationof diabetes mellitus and its complications
WHO Consultation (1999)
Risk of development of diabetes mellitus after diagnosis of gestationaldiabetes.CMAJ : Canadian MedicalAssociation journal1⁄4Journal de l’Association Medicale Canadienne 2008;179:229–234
DS Feig (2008)
10.1056/NEJM199309303291401
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group.
P. Saenger (1993)
10.1001/archinternmed.2010.334
Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial.
R. Wing (2010)
10.1093/eurheartj/15.suppl_B.2
Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study.
L. Moyé (1994)
10.1056/NEJMoa1001288
Effects of medical therapies on retinopathy progression in type 2 diabetes.
E. Chew (2010)
10.1016/j.jacc.2012.01.020
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
K. Swedberg (2012)
10.1001/jama.2017.20813
Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study
S. Ikramuddin (2018)
10.1016/j.jacc.2012.02.059
An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials.
M. O'Donoghue (2012)
ESC guidelines on the management of stable coronary artery disease — addenda The Task Force on the management of stable coronary artery disease of the European Society of Cardiology
U. Sechtem (2013)
10.1097/HJH.0000000000000881
Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels – updated overview and meta-analyses of randomized trials
C. Thomopoulos (2016)
10.1161/CIRCULATIONAHA.117.032038
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
Kenneth W. Mahaffey (2018)
EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION
B. Pitt (2003)
10.1093/oxfordjournals.eurheartj.a059591
Diabetic patients and beta-blockers after acute myocardial infarction.
J. Kjekshus (1990)
10.2337/dc08-0577
Effect of Aging on A1C Levels in Individuals Without Diabetes
L. Pani (2008)
10.1016/S0002-9149(99)00392-6
Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites.
W. Aronow (1999)
10.1001/jama.1991.03460050081025
Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study.
E. Barrett-connor (1991)
10.2337/DIACARE.24.12.2091
Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project.
L. Niskanen (2001)
10.1186/1472-6963-7-55
Patient adherence to medical treatment: a review of reviews
S. van Dulmen (2007)
10.1001/JAMA.294.3.334
Insulin resistance and risk of congestive heart failure.
E. Ingelsson (2005)
10.1016/J.AHJ.2004.07.005
Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure.
S. Smooke (2005)
10.2337/DIACARE.28.3.668
Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study.
E. Schroeder (2005)
10.1161/JAHA.113.000354
Effectiveness of Percutaneous Coronary Intervention With Drug‐Eluting Stents Compared With Bypass Surgery in Diabetics With Multivessel Coronary Disease: Comprehensive Systematic Review and Meta‐analysis of Randomized Clinical Data
A. Hakeem (2013)
10.1016/J.JVS.2005.02.005
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.
L. Sjöström (2004)
10.1001/archinternmed.2011.275
Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial.
T. Saito (2011)
10.1161/CIRCULATIONAHA.108.836346
Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy
S. Sorrentino (2010)
10.1093/eurheartj/ehv134
Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes.
P. Seferovic (2015)
10.1056/NEJMOA065061
Effect of ramipril on the incidence of diabetes.
J. Bosch (2006)
10.1056/NEJMoa1602001
Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy.
E. Velazquez (2016)
10.1371/journal.pone.0139907
The Health Effects of Passive Smoking: An Overview of Systematic Reviews Based on Observational Epidemiological Evidence
Shiyi Cao (2015)
10.1056/NEJMoa1412168
Everolimus-eluting stents or bypass surgery for multivessel coronary disease.
S. Bangalore (2015)
10.1007/s12325-015-0261-x
Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease
R. Roussel (2015)
10.1016/J.EHJ.2004.09.021
Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction.
M. Bartnik (2004)
10.1111/j.1464-5491.2010.03183.x
HbA1c in diagnosing and predicting Type 2 diabetes in impaired glucose tolerance: the Finnish Diabetes Prevention Study
P. Pajunen (2011)
10.1074/jbc.M303810200
Diabetes and the Accompanying Hyperglycemia Impairs Cardiomyocyte Calcium Cycling through Increased Nuclear O-GlcNAcylation*
R. Clark (2003)
10.1093/eurheartj/ehq325
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
S. James (2010)
10.1136/bmj.e5900
Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study
A. Abbasi (2012)
10.1016/j.diabet.2018.05.003
Haemoglobin A1c and 5-year all-cause mortality in French type 2 diabetic patients aged 70 years and older: The GERODIAB observational cohort.
J. Doucet (2018)
10.1016/j.amjmed.2008.07.027
The impact of revascularization on mortality in patients with nonacute coronary artery disease.
A. Jeremias (2009)
10.1016/J.JACC.2004.05.041
Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI).
E. Alderman (2004)
10.1016/S0140-6736(18)31506-X
Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study
Araz Rawshani (2018)
10.1136/hrt.2005.086975
Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart
M. Bartnik (2006)
10.1111/1753-0407.12304
Intensive walking exercise for lower extremity peripheral arterial disease: A systematic review and meta‐analysis
X. Lyu (2016)
10.1177/2047487312444371
Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes
C. Hage (2013)
10.1056/NEJMoa1804989
Effects of n‐3 Fatty Acid Supplements in Diabetes Mellitus
L. Bowman (2018)
10.1016/S0735-1097(01)01183-4
New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study.
F. Ledru (2001)
ON OXIDATIVE STRESS AND DIABETIC COMPLICATIONS
Vinod. Patel (2013)
10.1056/NEJMoa1009492
Eplerenone in patients with systolic heart failure and mild symptoms.
F. Zannad (2011)
10.1007/s00125-003-1116-6
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
S. Laing (2003)
Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group.
I. Gustafsson (1999)
10.1161/CIRCULATIONAHA.108.780999
Metabolic Management of Acute Myocardial Infarction Comes to the Fore and Extends Beyond Control of Hyperglycemia
L. Opie (2008)
10.1111/dom.13114
Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial
Lawrence A Leiter (2017)
10.1007/s00125-017-4422-0
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
T. Pieber (2017)
10.3132/dvdr.2008.046
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
J. Fruchart (2008)
10.1016/j.ejvs.2009.06.002
Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies.
A. H. Momsen (2009)
10.1016/S0140-6736(06)69420-8
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
H. Gerstein (2006)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial
HM Colhoun (2004)
Lipidmodifying therapies and risk of pancreatitis: a meta-analysis
D Preiss (2012)
GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial
S E Nissen (2016)
10.1161/01.STR.0000020091.07144.C7
UKPDS 60: Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine
V. Kothari (2002)
38 8.4.1 Renin-angiotensin-aldosterone system and a neprilysin inhibitors
. . . . . . . . . . . . Mellitus
Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
B M Scirica (2013)
Kyrgyzstan: Kyrgyz Society of Cardiology, Saamai Abilova; Latvia: Latvian Society of Cardiology
Kosovo
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients 66 ESC
J P Seferovic
10.2337/dc15-2322
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON
M. G. Wong (2016)
10.1016/j.jacc.2017.07.792
Clinical Implications of Echocardiographic Phenotypes of Patients With Diabetes Mellitus.
L. Ernande (2017)
10.1056/NEJMOA072761
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
S. Nissen (2007)
10.1159/000484633
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
M. Jardine (2017)
10.1016/J.YEND.2011.05.023
Downregulation of Adipose Tissue Fatty Acid Trafficking in Obesity: A Driver for Ectopic Fat Deposition?
M. Ruth (2011)
10.1016/S0140-6736(09)60552-3
Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials
M. Hlatky (2009)
10.1016/j.pharmthera.2010.01.008
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
M. Chapman (2010)
10.2337/DIACARE.28.10.2345
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.
D. Eurich (2005)
10.1007/s00125-008-1177-7
Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes—the ‘dead in bed’ syndrome revisited
G. Gill (2008)
10.1111/j.1365-2648.2009.05040.x
Instruments to tailor care of people with type 2 diabetes.
A. Sigurdardottir (2009)
10.1016/j.ijcard.2016.12.116
Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials.
Chirag P Bavishi (2017)
10.15829/1560-4071-2014-3-7-61
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of theEuropeanSocietyofCardiology(ESC)anddevelopedincollaboration
L. Rydén (2014)
Abstract 3735: Glucose Lowering Therapy in Post Myocardial Infarction Patients with Diabetes - is Insulin Safe? A report from the Euro Heart Survey on Diabetes and the Heart
M. Anselmino (2007)
10.1007/s00592-009-0157-9
Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study
Anna Kucharska-Newton (2009)
10.1016/j.jacc.2009.10.061
Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis.
C. Vlachopoulos (2010)
10.1016/J.JACC.2003.11.024
Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure.
I. Gustafsson (2004)
10.1053/HJ.1998.V136.90226
Sudden coronary death in women.
W. Kannel (1998)
10.1093/eurheartj/ehy394
2018 ESC/EACTS Guidelines on myocardial revascularization.
Franz-Josef Neumann (2019)
10.1056/NEJMoa1501352
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
J. Green (2015)
10.1007/s00125-014-3460-0
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
S. Inzucchi (2014)
10.1016/S0735-1097(02)02346-X
Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry.
S. Sedlis (2002)
10.1016/j.ophtha.2011.01.031
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
P. Mitchell (2011)
10.1093/EURHEARTJ/EHL363
Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart.
M. Lenzen (2006)
10.1016/S0140-6736(03)13800-7
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
P. Poole-wilson (2003)
10.1016/J.JVS.2012.10.058
Common Carotid Intima-Media Thickness Measurements in Cardiovascular Risk Prediction: A Meta-Analysis
H. Ruijter (2012)
10.1056/NEJMoa1212914
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.
R. Wing (2013)
10.1111/j.1538-7836.2012.04723.x
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low‐dose aspirin in patients with and without diabetes
B. Rocca (2012)
10.2337/dc08-0662
Risk Prediction of Cardiovascular Disease in Type 2 Diabetes
J. Cederholm (2008)
10.1056/NEJM198402093100605
Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes.
C. Mogensen (1984)
10.1056/NEJMOA073394
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
P. Home (2007)
10.1016/J.HEALUN.2006.06.008
Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006.
M. Mehra (2006)
10.1007/s00125-011-2078-8
Haemoglobin A1c levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts
R. Santos-Oliveira (2011)
10.1002/14651858.CD003417.PUB2
Group based training for self-management strategies in people with type 2 diabetes mellitus.
T. Deakin (2005)
10.1016/J.JACC.2005.01.039
The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease.
G. Hu (2005)
10.1016/j.recesp.2011.09.014
[ESC/EAS Guidelines for the management of dyslipidaemias].
Ž. Reiner (2011)
10.1056/NEJMRA052717
Low-dose aspirin for the prevention of atherothrombosis.
C. Patrono (2005)
10.1016/S0008-6363(96)00263-5
Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study.
K. Malmberg (1997)
10.1136/bmj.324.7330.141
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
Trialists Antithrombotic (2002)
Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure
DavidAguilar (2011)
Lowdose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial
Y Saito (2017)
10.1007/s00125-003-1210-9
Trends in hypertension management in Type I diabetes across Europe, 1989/1990 – 1997/1999
S. Soedamah-Muthu (2003)
Risk estimation and the prevention of cardiovascular disease
(2007)
10.1007/s00592-008-0090-3
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
K. Pantalone (2008)
10.1093/eurheartj/ehx393
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).
B. Ibanez (2018)
10.1016/S0140-6736(17)30819-X
Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015
Marissa B Nancy Marie Joseph S Amanuel Kalkidan Hassen Cri Reitsma Fullman Ng Salama Abajobir Abate Abbafati (2017)
10.1136/dtb.1994.321183
Diuretics for heart failure
René R. Wenzel (1986)
10.1016/S0140-6736(09)60503-1
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
Antithrombotic Trialists' (ATT) Collaboration (2009)
10.1056/NEJMoa1203859
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
J. Bosch (2012)
Effects of beta-blockers on glucose and lipid metabolism
VA Fonseca (2010)
Independent risk factors for atrial fibrillation in a population-based cohort
EJ Benjamin (1994)
A trial of ESC Guidelines 3087i by gest on Jauary 27, 2015 D ow nladed fom darbepoetin alfa in type 2 diabetes and chronic kidney disease
MA Pfeffer (2009)
10.1016/j.jcin.2008.02.005
Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry.
S. Mulukutla (2008)
10.1007/s00125-016-4065-6
Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial
P. Gæde (2016)
10.1136/bmjopen-2017-017184
Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes
S. Roberts (2017)
10.1056/NEJMoa1611925
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
B. Neal (2017)
10.2337/dc08-1543
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome
R. Scott (2009)
10.1097/HJR.0b013e32833ba61e
Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register
M. Eriksson (2011)
10.1007/s12529-012-9242-5
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)
J. Perk (2012)
10.1161/CIRCRESAHA.112.266593
Gene Silencing of the Mitochondrial Adaptor p66Shc Suppresses Vascular Hyperglycemic Memory in Diabetes
F. Paneni (2012)
10.7326/0003-4819-141-6-200409210-00006
Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk
K. Khaw (2004)
Yusuf S; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind
S S Anand (2018)
10.1016/j.jacc.2011.07.005
Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data.
D. Capodanno (2011)
10.1056/NEJMOA066139
Coronary intervention for persistent occlusion after myocardial infarction.
J. Hochman (2006)
10.1002/ejhf.288
Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial
M. Macdonald (2015)
10.1016/j.metabol.2014.09.006
Increased glycemic variability and decrease of the postprandial glucose contribution to HbA1c in obese subjects across the glycemic continuum from normal glycemia to first time diagnosed diabetes.
M. Fysekidis (2014)
10.1007/164_2016_76
Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
P. Kolkhof (2017)
10.1177/1074248416644987
Effects of Carvedilol Compared to Nebivolol on Insulin Resistance and Lipid Profile in Patients With Essential Hypertension
Ali Gökhan Ozyıldız (2017)
10.1161/CIRCULATIONAHA.114.010389
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
B. Scirica (2014)
10.1056/NEJMOA043399
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
G. Bardy (2005)
10.1097/FJC.0b013e318202709f
Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis
E. Bruckert (2011)
10.1016/S0084-3873(11)00270-7
Diabetic and Nondiabetic Patients With Left Main and/or 3-Vessel Coronary Artery Disease: Comparison of Outcomes With Cardiac Surgery and Paclitaxel-Eluting Stents
V. Thourani (2011)
10.1160/TH11-04-0216
Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications.
G. Spectre (2011)
10.1001/JAMA.292.18.2227
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
G. Bakris (2004)
10.1093/eurheartj/eht150
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA).
M. Brignole (2013)
10.1016/J.JACC.2003.08.050
Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.
A. Norhammar (2004)
10.1161/CIRCRESAHA.109.213140
The promise of cell-based therapies for diabetic complications: challenges and solutions.
Y. Jarajapu (2010)
10.1016/j.jacc.2016.06.061
Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure.
I. Johansson (2016)
10.1016/j.amjcard.2017.11.021
Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus.
B. Gilbert (2018)
10.1016/J.ACCREVIEW.2003.10.014
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-alternative trial
C. Granger (2004)
10.1056/NEJM200111223452113
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
Patricia Campbell (2001)
10.3810/psm.2010.04.1764
The Role of Physical Activity in Type 2 Diabetes Prevention: Physiological and Practical Perspectives
J. Burr (2010)
10.7326/L16-0617
Effects on Health Outcomes of a Mediterranean Diet With No Restriction on Fat Intake.
H. Bloomfield (2017)
10.1161/CIRCULATIONAHA.110.016337
Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials
S. Bangalore (2011)
10.1016/S0140-6736(16)31535-5
Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial
J. Bolinder (2016)
10.1016/J.CMRP.2019.07.012
Canagliflozin And Renal Outcomes In Type 2 Diabetes And Nephropathy
A. Gogia (2019)
10.1016/S0140-6736(13)60141-5
Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial
F. W. Mohr (2013)
10.1016/J.CARDFAIL.2007.06.723
Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure.
J. Ghali (2007)
10.1161/01.CIR.0000154542.13412.B1
Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study
F. Masoudi (2005)
10.1016/S0145-4145(09)79524-3
Facilitated PCI in Patients with ST-Elevation Myocardial Infarction
B. Gersh (2009)
10.1056/NEJMoa0808400
Renal and retinal effects of enalapril and losartan in type 1 diabetes.
M. Mauer (2009)
10.2337/dc09-0615
Rates of Progression in Diabetic Retinopathy During Different Time Periods
T. Wong (2009)
10.1056/NEJM199209033271001
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
M. Pfeffer (1992)
10.1093/eurheartj/ehw272
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
A. Catapano (2016)
10.1016/S0002-9343(99)00126-6
Risk factors for heart failure in the elderly: a prospective community-based study.
Y. Chen (1999)
Motivational interviewing: a systematic review and meta-analysis.
S. Rubak (2005)
10.1007/S11883-008-0043-X
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
J. Liao (2008)
10.1056/NEJM199108013250501
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
S. Yusuf (1991)
10.1007/s13300-016-0223-6
Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial
T. Haak (2016)
10.1093/EURHEARTJ/EHL001
Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology.
F. Messerli (2006)
10.1016/J.AMEPRE.2005.07.030
Major coronary risk factors and death from coronary heart disease: baseline and follow-up mortality data from the Second National Health and Nutrition Examination Survey (NHANES II).
G. Mensah (2005)
10.2337/dc09-0939
Independent Contribution of Diabetes to Increased Prevalence and Incidence of Atrial Fibrillation
G. Nichols (2009)
10.1016/J.YCAR.2011.01.115
Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes
W. Elliott (2011)
10.1016/j.metabol.2014.10.018
Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis.
Liang Chen (2015)
10.1038/nrcardio.2016.162
Cardiovascular effects of bariatric surgery
A. Beamish (2016)
10.3399/bjgp09X394851
Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study.
P. Janssen (2009)
10.1161/CIRCHEARTFAILURE.115.002560
Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction
S. L. Kristensen (2016)
10.1016/S1474-4422(12)70159-X
Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial
B. Lal (2012)
10.1136/bmjdrc-2016-000259
Long-term effect of intensive lifestyle intervention on cardiovascular risk factors in patients with diabetes in real-world clinical practice: a 5-year longitudinal study
O. Hamdy (2017)
10.1186/s12933-018-0665-4
Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology
Bahira Shahim (2018)
10.1016/0002-8703(91)90861-B
Cardiovascular disease risk profiles.
K. M. Anderson (1991)
10.1016/S0140-6736(94)91963-1
Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration
S. Yusuf (1994)
5-yearoutcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study
B Lagerqvist (2006)
Arrhythmias: atrial fibrillation, ventricular arrhythmias, and sudden cardiac death
10.1093/eurheartj/ehp055
Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study.
X. Du (2009)
10.1001/jama.2009.476
Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial.
L. Young (2009)
10.1038/KISUP.2012.73
Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease
A. Levin (2013)
10.1002/14651858.CD000011.pub4
Interventions for enhancing medication adherence.
R. Nieuwlaat (2014)
10.1056/nejm199810293391821
THE EFFECT OF NISOLDIPINE AS COMPARED WITH ENALAPRIL ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES AND HYPERTENSION
AYMOND (2000)
10.1056/NEJMoa0901301
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
S. Connolly (2009)
10.1186/1472-6963-12-213
Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis
A. Steinsbekk (2012)
10.1056/NEJMoa1001122
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
R. Holman (2010)
10.3310/hta13150
Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial.
A. Farmer (2009)
10.2337/dc19-S002
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019
(2018)
10.1136/bmj.b4731
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
I. Tzoulaki (2009)
10.1007/s00125-017-4423-z
Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
B. Zinman (2017)
10.1136/BMJ.323.7322.1192
Crossing the Quality Chasm: A New Health System for the 21st Century
A. Baker (2001)
10.2337/DIACARE.26.3.855
Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study.
L. Vaur (2003)
10.1016/S0735-1097(03)00856-8
The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial.
M. Domanski (2003)
10.1093/europace/euq350
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
A. J. Camm (2010)
10.3109/08037051.2011.587288
Trends in blood pressure control in patients with type 2 diabetes – Data from the Swedish National Diabetes Register (NDR)
P. Nilsson (2011)
Diets for Health: Goals and Guidelines.
Amy B. Locke (2018)
10.1001/archinternmed.2009.439
Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis.
R. Huxley (2009)
10.1002/ejhf.1072
Renin inhibition in heart failure and diabetes: the real story
G. Rosano (2018)
10.1016/j.ejheart.2008.08.012
Left atrial velocity vector imaging for the detection and quantification of left ventricular diastolic function in type 2 diabetes
C. Jarnert (2008)
10.1111/j.1365-2796.2007.01824.x
Diabetes mellitus as a prothrombotic condition
P. Grant (2007)



This paper is referenced by
10.18794/aams/75367
Glucose abnormalities detected by oral glucose tolerance test in patients with acute myocardial infarction: clinical significance, epidemiology, natural course and therapeutic concerns
Paweł Francuz (2017)
10.1161/jaha.120.016292
Temporal Trends and Familial Clustering of Ideal Cardiovascular Health in Parents and Offspring Over the Life Course: An Investigation Using The Framingham Heart Study.
James M Muchira (2020)
10.1038/s41574-019-0294-3
Two drugs are better than one to start T2DM therapy
Francesco Prattichizzo (2019)
10.1210/er.2018-00017
Pathophysiology and Individualized Treatment of Hypothalamic Obesity Following Craniopharyngioma and Other Suprasellar Tumors: A Systematic Review.
Laura van Iersel (2019)
10.1007/s00059-019-4782-y
[Acute coronary syndrome : Prevention].
Uwe Nixdorff (2019)
10.1371/journal.pone.0194446
The simultaneous assessment of glycosylated hemoglobin, fasting plasma glucose and oral glucose tolerance test does not improve the detection of type 2 diabetes mellitus in Colombian adults
José Luis López-López (2018)
Metabolic risk markers and relative survival in patients with aortic stenosis requiring surgery
Anders Holmgren (2019)
10.1093/eurheartj/ehaa218
Supracardiac atherosclerosis in embolic stroke of undetermined source: the underestimated source.
George Ntaios (2020)
10.1016/j.redox.2020.101517
Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions
Nadezda Apostolova (2020)
10.5603/DK.2018.0005
Impact of physical activity on hypoglycaemia in patients with diabetes
K. Zielińska (2018)
10.3389/fphar.2020.01176
Medication Review by Community Pharmacists for Type 2 Diabetes Patients in Routine Care: Results of the DIATHEM-Study
Elisabeth Schindler (2020)
Diabetes mellitus and heart failure : registry based studies on risk factors, prognosis and impact of treatment
I. Johansson (2017)
10.2147/DMSO.S266901
Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
P. Men (2020)
10.1080/00325481.2019.1701864
Gender difference in the association of serum selenium with all-cause and cardiovascular mortality
J. Li (2019)
10.1080/17512433.2020.1766964
Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases
V. Panoulas (2020)
10.1016/J.JNUTBIO.2019.03.014
High fructose diet induces early mortality via autophagy factors accumulation in the rostral ventrolateral medulla as ameliorated by pioglitazone.
I. Lin (2019)
10.1016/j.atherosclerosis.2019.05.014
Epidemiology, risk factors, and opportunities for prevention of cardiovascular disease in individuals of South Asian ethnicity living in Europe.
Miguel Cainzos-Achirica (2019)
10.1002/9781119374800.CH39
Management of Diabetes and/or Hyperglycemia in Acute Coronary Syndrome, Acute Stroke, and Acute Heart Failure
Miles Mark Fisher (2018)
10.1016/j.coph.2018.03.001
Glucose‐lowering treatment in cardiovascular and peripheral artery disease
R. Suades (2018)
10.1177/1060028017747901
Efficacy and Safety of Ranolazine in Diabetic Patients: A Systematic Review and Meta-analysis
Xiaofang Zeng (2017)
10.12809/hkmj165045
2016 Consensus statement on prevention of atherosclerotic cardiovascular disease in the Hong Kong population.
Bernard Man Yung Cheung (2017)
10.1007/978-981-10-4307-9_12
Exercise Amaliorates Metabolic Disturbances and Oxidative Stress in Diabetic Cardiomyopathy: Possible Underlying Mechanisms.
Ayman M. Mahmoud (2017)
10.1016/s1131-3587(20)30014-5
TEMPORARY REMOVAL: Paciente con alto riesgo cardiovascular y fibrilación auricular: papel del rivaroxabán
Vivencio Barrios (2020)
10.1038/s41569-019-0225-y
Role of aspirin in primary prevention of cardiovascular disease
Carlo Patrono (2019)
10.1371/journal.pone.0211695
A prescription support-tool for chronic management of oral antithrombotic combinations in adults based on a systematic review of international guidelines
L. Zerah (2019)
10.1093/eurheartj/ehy677
Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable.
F. Cosentino (2018)
10.1093/eurheartj/ehy903
Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy
S. Costantino (2019)
10.1007/s11886-020-01355-5
Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist
Kershaw V. Patel (2020)
10.1177/2047487318809492
Unconventional approaches to diabetes screening: Rejuvenation time for cardiovascular prevention strategies?
L. Liberale (2018)
10.1007/s10557-019-06892-y
Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients
Munemitsu Otagaki (2019)
10.1007/s13300-020-00904-z
Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial
L. Wang (2020)
10.1111/joim.13101
COVID‐19 and renin‐angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) ‐ Is there any scientific evidence for controversy?
A. Aleksova (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar